| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Vericel Corporation$47
-1.31 (-2.71%)
C 42Pipeline Score Overvalued Biotech · Commercial
Market Cap
1.77 B
EPS
0.42
P/E Ratio
84.91 $
Value Trade
21.01 M
SEC Financials
Q1 2026Dilution Risk
Revenue
68.42 M
R&D Expenses
8.10 M
Operating CF
16.38 M
Total Assets
485.63 M
Total Liabilities
129.40 M
Equity
356.23 M
D/E Ratio
12,345
5.92 %
Week
2.39 %
1 Month
-8.32 %
3 Month
-8.39 %
6 Month
-34.47 %
5 Year
-96.9 %
All Time
Cash Data
Cash Position
145.34 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
May 7, 2026
Overview
Volume
451.85 K
52 Week Range
28.95 - 45.97
% held by Insiders
1.2 %
% held by Institutions
111.67 %
Enterprise Value
1.72 B
Total Shares
51.06 M
Short %
10.48 %
Float Shares
47.18 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Vericel Corporation
517Total events
5Upcoming
113Tier-1 (high impact)
2013 – 2029Coverage
Upcoming catalysts 5
Event history 512
Jun 16, 2026
◆Oral PresentationPresentation
Vericel to present at 2026 Truist Securities MedTech Conference
May 7, 2026
▲FDA ApprovalMACIApprovedFDA Decision
FDA approval for MACI commercial manufacturing at new Burlington facility
cartilage defects of the kneesource ↗
May 7, 2026
▲Partnership / LicenseNexoBridApprovedCorporate
BARDA award valued at up to $197 million for procurement and advanced development of NexoBrid
eschar removal in thermal burnssource ↗
May 7, 2026
▲Timing GuidancePresentation
Full-year 2026 revenue guidance raised by $10 million to $326-$336 million
Q2 2026
▲Product LaunchMACIApprovedPost-Market
Start of commercial production of MACI at new facility
repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adultssource ↗
Apr 1, 2026
▲Partnership / LicenseNexoBridApprovedCorporate
BARDA contract award for procurement and advanced development of NexoBrid
severe thermal burns and blast trauma injuriessource ↗
Mar 10, 2026
Mar 4, 2026
▲FDA ApprovalMACIApprovedFDA Decision
FDA approval for MACI commercial manufacturing at Burlington facility
repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adultssource ↗
Feb 26, 2026
Drug Pipeline Intelligence
C42
Pipeline Score $390M
Pipeline ValueOvervalued
Valuation Signal3
Drugs Scored0.2x
rNPV / MCap Top 60%
Micro Cap (rank 365 of 911)
Percentile RankVericel Corporation carries a moderate pipeline score (42/100), with $974M risk-adjusted pipeline value, led by Ixmyelocel-T in Critical Limb Ischemia (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ixmyelocel-T Monoclonal antibody | Osteonecrosis | Phase 3 | NCT00505219 | 57% | $742M | COMPLETED | 11 | - | - | Dec 1, 2010 | - | Oct 21, 2019 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
NexoBrid | deep thermal burns | Phase 3 | 2023-09-28 | More than 93% of the patients treated with NexoBrid achieved complete eschar removal following one application of NexoBrid compared with 4% in the GV arm (P<0.0001); Surgical excision was lower in the NexoBrid arm when compared to the SOC group (4% vs. 72%; P<0.001); The estimated median time to complete eschar removal was 1.02 and 3.83 days for the NexoBrid and SOC treatment arms, respectively (P<0.0001) Read More | Vericel Announces Publication of Positive Results from Phase 3 Debride and Protect (DETECT) Study of Thermal Burn Patients Treated with NexoBrid Read More | |
NexoBrid | deep thermal burns | Phase 3 | 2023-09-28 | More than 93% of the patients treated with NexoBrid achieved complete eschar removal following one application of NexoBrid compared with 4% in the GV arm (P<0.0001); Surgical excision was lower in the NexoBrid arm when compared to the SOC group (4% vs. 72%; P<0.001); The estimated median time to complete eschar removal was 1.02 and 3.83 days for the NexoBrid and SOC treatment arms, respectively (P<0.0001) Read More | Vericel Announces Publication of Positive Results from Phase 3 Debride and Protect (DETECT) Study of Thermal Burn Patients Treated with NexoBrid Read More | |
NexoBrid | deep thermal burns | Phase 3 | 2023-09-28 | More than 93% of the patients treated with NexoBrid achieved complete eschar removal following one application of NexoBrid compared with 4% in the GV arm (P<0.0001); Surgical excision was lower in the NexoBrid arm when compared to the SOC group (4% vs. 72%; P<0.001); The estimated median time to complete eschar removal was 1.02 and 3.83 days for the NexoBrid and SOC treatment arms, respectively (P<0.0001) Read More | Vericel Announces Publication of Positive Results from Phase 3 Debride and Protect (DETECT) Study of Thermal Burn Patients Treated with NexoBrid Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in VCEL
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
VCEL Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
VCELVericel to Present at the 2026 Truist Securities MedTech Conference on Tuesday, June 16, 2026
Vericel Corporation announced its participation in the 2026 Truist Securities MedTech Conference scheduled for June 16, 2026. The presentation will highlight the company's advanced therapies for sports medicine and severe burn care. A webcast will be available on Vericel's Investor Relations website for those interested in the presentation.
Read more →VCELVericel Reports First Quarter 2026 Financial Results and Raises Full-Year Financial Guidance
Vericel Corporation announced strong financial results for the first quarter of 2026, with total revenue increasing by 30% to $68.4 million. Key areas of growth included MACI revenue, which grew by 22%, and Burn Care revenue, which surged by 91%. The company also reported a significant increase in adjusted EBITDA, up 195% to $9.6 million. Notably, Vericel has raised its full-year revenue guidance by $10 million, reflecting confidence in sustained growth. Despite a reported net loss, the firm holds substantial cash reserves and remains on track for future profit and operational targets.
Read more →VCELVERICEL CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands - unaudited) March 31
Vericel Corporation (NASDAQ: VCEL) announced strong financial results for the first quarter of 2026, with total revenues increasing by 30% to $68.4 million. Notable segments included a 22% growth in MACI revenue and a remarkable 91% increase in Burn Care revenue. The company also reported a significant rise in adjusted EBITDA by 195%, but recorded a net loss of $6.3 million. Additionally, Vericel raised its full-year revenue guidance by $10 million, reflecting positive future prospects.
Read more →VCELVericel to Report First-Quarter 2026 Financial Results on May 7, 2026
Vericel Corporation will announce its first-quarter 2026 financial results on May 7, 2026. A conference call and webcast will be held at 8:30 a.m. ET to discuss these results and business highlights. The live webcast will be accessible via the company's Investor Relations website, with a replay available for one year.
Read more →VCELVericel Announces BARDA Award Valued at up to $197 Million for Procurement and Advanced Development of NexoBrid
Vericel Corporation has secured a ten-year contract worth up to $197 million from BARDA for the procurement and development of NexoBrid. The contract includes initial funding for establishing a Vendor Managed Inventory system and developing a next-generation formulation. This partnership aims to enhance U.S. preparedness for mass casualty events involving severe burns and blast trauma injuries.
Read more →VCELVericel Announces FDA Approval of New State-of-the-Art Advanced Therapy Manufacturing Facility
Vericel Corporation has received FDA approval for its new advanced therapy manufacturing facility in Burlington, Massachusetts. This approval allows for the commercial production of MACI, a cartilage repair product, starting in Q2 2026. The facility will significantly increase manufacturing capacity and supports potential commercialization of MACI outside the United States.
Read more →VCELVericel to Present at Multiple Upcoming Investor Conferences
Vericel Corporation has announced its participation in several upcoming investor conferences, including the TD Cowen 46th Annual Healthcare Conference and the Leerink Partners 2026 Global Healthcare Conference. The presentations will highlight the company's advanced therapies for sports medicine and severe burn care. Webcasts of the events will be available on Vericel's Investor Relations website.
Read more →VCELVericel Reports Fourth Quarter and Full-Year 2025 Financial Results
Vericel Corporation reported strong financial results for Q4 and full-year 2025, with total revenue of $276.3 million and a 21% growth in MACI revenue. The company achieved a record gross margin of 79% in Q4 and a net income increase of 59%. CEO Nick Colangelo expressed optimism for continued growth in 2026, despite rising operating expenses.
Read more →VCELVericel Corporation 64 Sidney Street Cambridge, MA 02139 T (617) 588-5555 F (617) 588-5554 www.vcel.com Vericel Reports Fourth Quarter and Full-Year 2025 Financial Results Total Revenue of $276.3 Million, with MACI Reven
Vericel Corporation reported strong financial results for the fourth quarter and full year 2025, with a total revenue of $276.3 million, representing a growth of 16% year-over-year. The MACI product line saw revenue growth of 21% to $239.5 million, and the company's net income grew by 59% to $16.5 million. Notably, the fourth quarter also recorded a gross margin of 79%, alongside an adjusted EBITDA margin of 40%. Looking ahead, Vericel is aiming for total revenue between $316 million and $326 million for 2026, indicating confidence and growth potential.
Read more →VCELVericel to Report Fourth-Quarter and Full-Year 2025 Financial Results on February 26, 2026
Vericel Corporation will announce its fourth-quarter and full-year 2025 financial results on February 26, 2026. The company will host a conference call and webcast at 8:30 a.m. ET to discuss these results and business highlights. Investors can access the live webcast and presentation slides on the company's website.
Read more →VCELVericel Announces Preliminary 2025 Financial Results and Business Updates
Vericel Corporation announced preliminary financial results for 2025, projecting total revenue of $276 million, with MACI revenue expected at $239.5 million. The company reported a 23% growth in both total revenue and MACI revenue for the fourth quarter. CEO Nick Colangelo expressed optimism for continued growth and profitability in 2026, highlighting the company's momentum.
Read more →VCELVericel Corporation 64 Sidney Street Cambridge, MA 02139 T 617 588-5555 F 617 588-5554 www.vcel.com Vericel Announces Preliminary 2025 Financial Results and Business Updates Total Revenue Expected to be $276 Million MACI
Vericel Corporation reported preliminary financial results for 2025, forecasting total revenue of $276 million, a significant increase. The MACI product line is anticipated to generate $239.5 million in revenue, marking a 23% growth in the fourth quarter. CEO Nick Colangelo highlighted the company's strong performance and momentum heading into 2026. However, the financial results are preliminary and subject to change, as ongoing internal reviews are underway.
Read more →VCEL▲ +6.1%on this news
Vericel to Present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026
Vericel Corporation has announced its participation in the upcoming 44th Annual J.P. Morgan Healthcare Conference, scheduled for January 14, 2026, at 2:15 p.m. ET. The presentation will be accessible via a webcast on the company's Investor Relations website. Vericel is noted for its innovative therapies in sports medicine and severe burn care, marketing three products in the U.S. market. This event represents an opportunity for Vericel to showcase its advancements and connect with the investment community.
Read more →VCELVericel to Present at the Stephens Annual Investment Conference on Thursday, November 20, 2025
Vericel Corporation announced its participation in the Stephens Annual Investment Conference on November 20, 2025. The company will engage in a fireside chat at 11:00 a.m. ET, which will be accessible via a webcast. Vericel is recognized for its advanced therapies in sports medicine and severe burn care.
Read more →VCELVericel Reports Third Quarter 2025 Financial Results
Vericel Corporation reported strong financial results for Q3 2025, achieving a record total revenue of $67.5 million, driven by a 25% increase in MACI revenue. The company also reported a net income of $5.1 million, a turnaround from a loss in the previous year. Operating cash flow reached $22.1 million, indicating robust financial health. However, rising operating expenses and uncertainties regarding future growth remain concerns.
Read more →VCELVERICEL CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands - unaudited) September 30
Vericel Corporation reported a robust performance in the third quarter of 2025, showcasing total revenues of $67.5 million and a significant growth of 25% in MACI revenues, which totaled $55.7 million. The company achieved a net income of $5.1 million, highlighting an upturn from the previous year's loss. Operating cash flow also reached a record $22.1 million, signaling strong operational efficiency. Furthermore, Vericel maintains a solid financial position with $185 million in cash and no debt, alongside reaffirming positive guidance for the full year.
Read more →VCELVericel to Report Third-Quarter 2025 Financial Results on November 6, 2025
Vericel Corporation has announced it will report its third-quarter 2025 financial results on November 6, 2025. The event will include a conference call and webcast at 8:30 a.m. ET, allowing investors to discuss financial results and business highlights. A replay of the webcast will be available for a year. Vericel is known for its innovative therapies in sports medicine and severe burn care.
Read more →VCELVericel to Present at the Wells Fargo Healthcare Conference on Thursday, September 4, 2025
Vericel Corporation will participate in a fireside chat at the Wells Fargo Healthcare Conference on September 4, 2025. The event will take place at 3:45 p.m. ET and will be accessible via a webcast on their Investor Relations website. Vericel is known for its advanced therapies in sports medicine and severe burn care.
Read more →VCEL▼ -14.1%on this news
VERICEL CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands - unaudited) June 30
Vericel Corporation reported strong financial results for the second quarter of 2025, with total revenue reaching $63.2 million, marking a 20% increase from the previous year. Notably, MACI revenue experienced 21% growth, reflecting a successful expansion of their products. The company's adjusted EBITDA soared by 112% to $13.4 million, underscoring significant profitability growth. Additionally, Vericel received FDA clearance for a Phase 3 MACI Ankle clinical study, enhancing their future growth prospects.
Read more →VCEL▼ -14.1%on this news
Vericel Reports Second Quarter 2025 Financial Results
Vericel Corporation reported its second quarter 2025 financial results, featuring a 20% increase in total revenue to $63.2 million. The MACI revenue grew by 21% to $53.5 million, alongside a significant increase in adjusted EBITDA by 112% to $13.4 million. The company also received FDA IND clearance for a Phase 3 clinical study for MACI Ankle, marking a positive step for its product pipeline. Despite a small net loss, Vericel anticipates continued revenue and profitability growth.
Read more →VCELVericel to Report Second-Quarter 2025 Financial Results on July 31, 2025
Vericel Corporation has announced it will report its second-quarter 2025 financial results on July 31, 2025. The company will host a conference call and webcast at 8:30 a.m. ET to discuss the results and business highlights. Investors can access the live webcast on Vericel's Investor Relations website.
Read more →VCELVericel to Present at the Truist Securities MedTech Conference on Tuesday, June 17, 2025
Vericel Corporation will participate in a fireside chat at the Truist Securities MedTech Conference on June 17, 2025, at 9:20 a.m. ET. The event will be accessible via a webcast on the company's Investor Relations website. Vericel specializes in advanced therapies for sports medicine and severe burn care, offering products like MACI and Epicel.
Read more →VCELVericel Reports First Quarter 2025 Financial Results and Raises Full-Year Profitability Guidance
Vericel Corporation reported strong financial results for Q1 2025, with record MACI revenue of $46.3 million and total revenue of $52.6 million. The company has trained approximately 400 MACI Arthro surgeons, contributing to over 30% growth in biopsy rates. Despite a net loss of $11.2 million, Vericel raised its full-year profitability guidance, anticipating continued revenue growth.
Read more →VCEL▲ +5.3%on this newsshared move
Vericel to Present at the Bank of America Securities 2025 Healthcare Conference on Wednesday, May 14, 2025
Vericel Corporation announced its participation in the Bank of America Securities 2025 Healthcare Conference, scheduled for May 14, 2025. The presentation will take place at 12:20 p.m. ET and will be accessible via a webcast on the company's Investor Relations website. Vericel specializes in advanced therapies for sports medicine and severe burn care.
Read more →VCELVericel to Report First-Quarter 2025 Financial Results on May 8, 2025
Vericel Corporation announced that it will report its first-quarter 2025 financial results on May 8, 2025. The announcement includes details about a conference call and webcast to discuss the results and business highlights. Investors can access the live webcast and participate via telephone to engage with the company's management. The information is set to foster transparency and communication between Vericel and its stakeholders.
Read more →VCEL▼ -6.1%on this newsshared move
Vericel Reports Fourth Quarter and Full-Year 2024 Financial Results
Vericel Corporation (NASDAQ:VCEL) reported robust financial results for the fourth quarter and full year of 2024, highlighting a total revenue increase of 20% to $237.2 million. The company achieved a record gross margin of 78% in the fourth quarter, along with a notable EBITDA growth of 58% to $53.4 million for the year. Vericel reaffirmed its strong financial guidance for 2025, predicting further revenue growth of 20% to 23%. Additionally, the company has made significant strides in training approximately 250 MACI Arthro surgeons and gearing up for the launch of MACI Ankle IND in 2025.
Read more →VCEL▼ -6.1%on this newsshared move
Vericel Corporation 64 Sidney Street Cambridge, MA 02139 T (617) 588-5555 F (617) 588-5554 www.vcel.com Vericel Reports Fourth Quarter and Full-Year 2024 Financial Results Full-Year Total Revenue Growth of 20% to $237.2
Vericel Corporation reported robust financial results for the fourth quarter and full year 2024, with total revenue increasing by 20% to $237.2 million. The company achieved record gross margins of 78% and a significant growth in adjusted EBITDA by 58% to $53.4 million. The MACI product line experienced notable success, with approximately 250 surgeons trained, while burn care revenues also grew significantly. Looking ahead, Vericel reaffirmed its financial guidance for 2025, projecting continued revenue growth of 20% to 23%.
Read more →VCELVericel to Report Fourth-Quarter and Full-Year 2024 Financial Results on February 27, 2025
Vericel Corporation has announced the reporting date for its fourth-quarter and full-year 2024 financial results, set for February 27, 2025. The company will host a conference call and webcast to discuss these results and key business highlights. Investors can access the live webcast through Vericel's Investor Relations website and a replay will be available for one year. Vericel is known for its advanced therapies in sports medicine and severe burn care, offering products like MACI, Epicel, and NexoBrid.
Read more →VCELVericel Announces Preliminary 2024 Financial Results, 2025 Financial Guidance and Increased Mid-Term Profitability Targets
Vericel Corporation reported preliminary financial results indicating a 20% revenue growth for the full year 2024 and a strong adjusted EBITDA growth of approximately 55%. The company's MACI product line is expected to contribute significantly, demonstrating the highest quarterly performance since its launch. Vericel also announced a revenue guidance for 2025, projecting a growth of 20% to 23% and an increase in mid-term profitability targets. The financial outlook reflects the company's operational success, with significant cash reserves and no debt.
Read more →VCELVericel Corporation 64 Sidney Street Cambridge, MA 02139 T 617 588-5555 F 617 588-5554 www.vcel.com Vericel Announces Preliminary 2024 Financial Results, 2025 Financial Guidance and Increased Mid-Term Profitability Targe
Vericel Corporation has announced its preliminary financial results for 2024, projecting a total revenue growth of 20% along with a significant adjusted EBITDA growth of 55%. The company also reported a record gross margin of approximately 77% for the fourth quarter. Looking ahead, Vericel has provided financial guidance for 2025, forecasting a revenue growth of 20% to 23%. The company's mid-term profitability targets have been increased, reflecting its strong operational performance and market momentum.
Read more →VCELVericel to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025
Vericel Corporation announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference, scheduled for January 15, 2025. The presentation will take place at 10:30 a.m. ET, and a webcast will be accessible on their Investor Relations website. Vericel is known for its advanced therapies in sports medicine and severe burn care, offering innovative products such as MACI, Epicel, and NexoBrid.
Read more →VCELVericel Reports Third Quarter 2024 Financial Results
Vericel Corporation reported strong financial results for the third quarter of 2024, with total revenue growing by 27% to $57.9 million, alongside significant gains in adjusted EBITDA, which rose by 84%. The report highlighted record revenues for MACI and Epicel, as well as major regulatory achievements including FDA approval for MACI Arthro and a pediatric indication for NexoBrid. The company raised its profitability guidance, reflecting confidence in sustained growth through its innovative product portfolio. However, Vericel recorded a net loss of $0.9 million for the quarter.
Read more →VCELVericel to Report Third-Quarter 2024 Financial Results on November 7, 2024
Vericel Corporation announced that it will report its third-quarter 2024 financial results on November 7, 2024. The management will host a conference call and webcast to discuss the financial performance and key business highlights. Investors can participate through the webcast or telephone registration, with replays available for up to a year post-announcement. Vericel is recognized for its advanced therapies in the sports medicine and severe burn care sectors.
Read more →VCELVericel to Present at the Morgan Stanley Global Healthcare Conference on Friday, September 6, 2024
Vericel Corporation announced that its President and CEO, Nick Colangelo, along with CFO Joe Mara, will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on September 6, 2024. The presentation is set to take place at 1:05 p.m. ET. The event will be accessible via a webcast on Vericel's Investor Relations website. Vericel is known for its advanced therapies in sports medicine and severe burn care.
Read more →VCELVericel Corporation 64 Sidney Street Cambridge, MA 02139 T 617 588-5555 F 617 588-5554 www.vcel.com Vericel Announces FDA Approval and Commercial Availability of MACI Arthro First Restorative Biologic Cartilage Repair Pr
Vericel Corporation has received FDA approval for MACI Arthro, a new procedure that allows less invasive delivery of MACI for repairing knee cartilage defects. This breakthrough targets a substantial segment of the $3 billion addressable market, enhancing its position within the orthopedic sector. The approval marks a strategic advancement in providing innovative treatments for patients suffering from knee cartilage issues. MACI Arthro is anticipated to boost Vericel's revenue growth by reaching a broader surgeon audience.
Read more →VCELVericel Announces FDA Approval and Commercial Availability of MACI Arthro
Vericel Corporation has received FDA approval for its MACI Arthro product, facilitating a less invasive arthroscopic treatment for knee cartilage defects. This new technique is expected to enhance patient outcomes and increase market penetration significantly. The approval aligns with Vericel's strategy to innovate in cartilage repair, expanding its target surgeon base by 40%. The MACI Arthro product is notable as it becomes the first FDA-approved restorative biologic for such procedures in the United States.
Read more →VCELVericel Corporation 64 Sidney Street Cambridge, MA 02139 T 617 588-5555 F 617 588-5554 www.vcel.com Vericel Announces FDA Approval of NexoBrid for the Treatment of Pediatric Patients with Severe Thermal Burns Approval Ex
Vericel Corporation has announced the FDA's approval of NexoBrid for pediatric use in treating severe thermal burns, allowing approximately 20 pediatric burn centers in the U.S. to incorporate this novel non-surgical treatment into their care protocols. This decision is based on results from the global Phase 3 CIDS clinical trial, which highlighted the medication's safety and efficacy in pediatric patients. The approval is anticipated to significantly enhance the management of burn injuries in children, as it offers a less invasive alternative compared to traditional methods. Vericel aims to further the commercial launch and expand access to this treatment.
Read more →VCELVericel Announces FDA Approval of NexoBrid for the Treatment of Pediatric Patients with Severe Thermal Burns
Vericel Corporation announced FDA approval for NexoBrid, allowing its use in pediatric patients with severe thermal burns. This expands the product’s application to around 20 pediatric burn centers in the U.S., based on successful results from the Children Innovation Debridement Study. NexoBrid is positioned as a non-surgical treatment alternative, potentially changing the standard of care in pediatric burn management. However, concerns regarding hypersensitivity reactions and other potential adverse effects persist.
Read more →VCELVericel to Present at the Canaccord Genuity Growth Conference on Wednesday, August 14, 2024
Vericel Corporation announced that its President and CEO, Nick Colangelo, will present at the Canaccord Genuity Growth Conference on August 14, 2024. The presentation will take place at 3:00 p.m. ET and will be accessible via a webcast on Vericel's Investor Relations website. Vericel specializes in advanced therapies for sports medicine and severe burn care, offering products like MACI® and Epicel® among others. This event highlights the company’s commitment to engaging with investors and promoting its innovative therapies.
Read more →VCEL▼ -5.9%on this news
Vericel Reports Second Quarter 2024 Financial Results
Vericel Corporation reported strong financial results for the second quarter of 2024, with total net revenue reaching $52.7 million, driven by a 21% growth in MACI revenue. The company also achieved a gross margin of 70% and a 42% increase in adjusted EBITDA. Despite a net loss of $4.7 million, Vericel reaffirmed its full-year revenue guidance, indicating confidence in sustained growth. The company is also progressing with product launches and anticipates FDA approval for a pediatric indication for NexoBrid in the upcoming quarter.
Read more →VCELVericel Announces Appointment of Karen Mahoney as Chief Human Resources Officer
Vericel Corporation has announced the appointment of Karen Mahoney as the new Chief Human Resources Officer, succeeding Heidi Hassen. Mahoney comes to Vericel with over 20 years of experience, previously serving as the Chief HR Officer at Abiomed, which was acquired by Johnson & Johnson. Vericel's CEO, Nick Colangelo, expressed confidence in Mahoney's ability to lead the company towards continued growth and success. Mahoney aims to enhance Vericel's patient-focused culture and further attract and retain top talent.
Read more →VCELVericel to Report Second-Quarter 2024 Financial Results on August 1, 2024
Vericel Corporation has announced it will report its second-quarter 2024 financial results on August 1, 2024. The company will hold a conference call and webcast at 8:30 a.m. ET to discuss these results and other business highlights. Interested parties can access the live webcast on the Investor Relations section of Vericel's website and will also have the option to participate by telephone. A replay of the webcast will be available for a year following the event.
Read more →VCELVericel to Present at the Truist Securities MedTech Conference on Tuesday, June 18, 2024
Vericel Corporation will present at the Truist Securities MedTech Conference on June 18, 2024. CEO Nick Colangelo and CFO Joe Mara will participate in a fireside chat at the event. The presentation will be webcasted and is accessible on Vericel's Investor Relations website. Vericel is known for its advanced therapies in sports medicine and burn care, with several notable products marketed in the U.S.
Read more →VCELVericel to Present at the Leerink Partners Healthcare Crossroads Conference on Wednesday, May 29, 2024
Vericel Corporation has announced the participation of President and CEO Nick Colangelo and CFO Joe Mara in a fireside chat at the Leerink Partners Healthcare Crossroads Conference scheduled for May 29, 2024. The event highlights Vericel's role in advanced therapies for the sports medicine and severe burn care markets. A webcast of the presentation will be available on the company's Investor Relations website, indicating their commitment to engaging with investors and stakeholders. Vericel is well known for its innovative product offerings in the fields of cartilage repair and burn treatment.
Read more →VCELVericel Reports First Quarter 2024 Financial Results and Raises Full-Year 2024 Financial Guidance
Vericel Corporation reported strong financial results for the first quarter of 2024, including a 25% increase in total revenue to $51.3 million. The company's MACI revenue reached a record of $40.2 million, and burn care revenue grew by 63%. Adjusted EBITDA showed remarkable improvement, climbing 325% to $7.2 million, leading to an optimistic full-year revenue guidance of $238-$242 million. However, despite this growth, the company reported a net loss of $3.9 million and increased operating expenses due to ongoing development activities.
Read more →VCELVericel to Report First-Quarter 2024 Financial Results on May 8, 2024
Vericel Corporation will report its first-quarter 2024 financial results on May 8, 2024, and will hold a conference call at 8:30 a.m. ET to discuss the results and highlight its business activities. The investor relations section of the Vericel website will host the live webcast, and registration is recommended at least 15 minutes prior to the event. A replay of the webcast will be accessible on their website for one year.
Read more →VCELVericel Corporation 64 Sidney Street Cambridge, MA 02139 T (617) 588-5555 F (617) 588-5554 www.vcel.com Vericel Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Full-Year 2024 Financial Guidance F
Vericel Corporation reported strong financial results for fourth quarter and full-year 2023, highlighting a total revenue growth of 20%, reaching $197.5 million. The company also experienced significant profitability improvements, with net income increasing by 119% to $13 million in the fourth quarter. For 2024, Vericel provided guidance for continued revenue growth, expecting total revenues to be between $237 to $241 million. Notably, the company has made significant strides in its MACI and Burn Care franchises, which are expected to drive further success moving forward.
Read more →VCELVericel Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Full-Year 2024 Financial Guidance
Vericel Corporation (NASDAQ:VCEL) reported strong financial results for the fourth quarter and full-year 2023, with net revenues increasing by 23% in Q4 and 20% overall for the year. The company also provided optimistic guidance for 2024, anticipating total revenue between $237 million and $241 million. Despite a net loss of $3.2 million in 2023, this represented a significant improvement from the previous year's loss. Notably, the company highlighted successful growth in its MACI and Burn Care product lines, along with the successful commercial launch of NexoBrid.
Read more →VCELVericel to Present at the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024
Vericel Corporation announced that its President and CEO, Nick Colangelo, along with CFO, Joe Mara, will participate in a fireside chat at the TD Cowen 44th Annual Health Care Conference on March 5, 2024. This event reflects Vericel's commitment to engaging with investors and stakeholders in the healthcare sector. A webcast of the presentation will be accessible via Vericel's Investor Relations webpage, emphasizing the company's dedication to communication and transparency.
Read more →VCELVericel to Report Fourth-Quarter and Full-Year 2023 Financial Results on February 29, 2024
Vericel Corporation (NASDAQ:VCEL) is set to report its fourth-quarter and full-year 2023 financial results on February 29, 2024. The management will host a conference call and webcast at 8:30 a.m. (ET) to discuss the financial results and business highlights. Interested parties can access the live webcast through the Investor Relations section of Vericel's website. The report may provide insights into the company's performance in the advanced therapies market.
Read more →VCELVericel to Present at the Canaccord Genuity Musculoskeletal Conference on Monday, February 12, 2024
Vericel Corporation, known for its advanced therapies in sports medicine and severe burn care, announced that its President and CEO, Nick Colangelo, will present at the Canaccord Genuity Musculoskeletal Conference on February 12, 2024. The presentation is set to start at 11:00 a.m. ET, and a webcast will be available on the company's investor relations website. This event may serve as a platform to enhance Vericel's visibility among investors and industry leaders.
Read more →VCEL▲ +7.2%on this news
Vericel Corporation 64 Sidney Street Cambridge, MA 02139 T 617 588-5555 F 617 588-5554 www.vcel.com Vericel Announces Preliminary Full-Year and Fourth Quarter 2023 Financial Results Full-Year Total Revenue Expected to be
Vericel Corporation has announced preliminary financial results for 2023, highlighting a total revenue expectation of approximately $197.5 million, representing a growth of 20%. Notably, the company's MACI product is projected to achieve approximately $164.8 million in revenue, reflecting a 25% increase. The fourth quarter alone saw a revenue growth of 23%, with a standout performance in burn care revenue, which grew by approximately 31%. Vericel's CEO expressed optimism about entering 2024 with strong momentum and further profitability.
Read more →VCEL▲ +7.2%on this news
Vericel Announces Preliminary Full-Year and Fourth Quarter 2023 Financial Results
Vericel Corporation has announced preliminary unaudited financial results for 2023, expecting total revenue of approximately $197.5 million, reflecting a 20% increase from the previous year. The company reports significant growth across its product lines, with MACI revenue projected at $164.8 million, a 25% rise, and burn care revenue seeing a 31% increase. The fourth quarter alone shows a revenue forecast of about $65 million, marking a 23% growth. Vericel emphasizes strong operational performance and looks forward to further advancements and product launches in 2024.
Read more →VCELVericel to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024
Vericel Corporation has announced that its President and CEO, Nick Colangelo, will present at the 42nd Annual J.P. Morgan Healthcare Conference scheduled for January 10, 2024. This event highlights the company's advancements in therapies for sports medicine and severe burn care. A webcast of the presentation will be accessible through their Investor Relations section online. Vericel is known for its innovative cell therapy products for challenging medical conditions.
Read more →VCELVericel Reports Third Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance
Vericel Corporation (VCEL) reported robust financial results for Q3 2023, with total revenue of $45.6 million, reflecting an 18% year-over-year growth. The company raised its full-year revenue guidance to between $192.5 million and $197.5 million, driven by strong performance in its MACI product line, which grew by 21%. Notably, Vericel achieved its 13th consecutive quarter of positive adjusted EBITDA, despite posting a net loss of $3.7 million for the quarter. The Q3 results were bolstered by high cash reserves and significant operational milestones, including advancements in its NexoBrid product availability.
Read more →VCELVericel to Present at the Stephens Annual Investment Conference
Vericel Corporation has announced its participation in the upcoming Stephens Annual Investment Conference, scheduled for November 15, 2023. CEO Nick Colangelo and CFO Joe Mara will engage in a fireside chat starting at 10:00 a.m. ET. Stakeholders can access a live webcast of the presentation on Vericel's investor relations website, which may provide insights into the company’s strategies and product offerings in advanced therapies for sports medicine and severe burn care.
Read more →VCELVericel to Report Third-Quarter 2023 Financial Results on November 8, 2023
Vericel Corporation announced that it will report its third-quarter 2023 financial results on November 8, 2023. The company, known for its advanced therapies for sports medicine and severe burn care, will host a conference call and webcast at 8:30 a.m. ET to discuss the results and business highlights. Investors can access the live webcast on the Vericel Investor Relations website and a replay will be available until November 8, 2024.
Read more →VCELVericel Announces Publication of Positive Results from Phase 3 Debride and Protect (DETECT) Study of Thermal Burn Patients Treated with NexoBrid
Vericel Corporation announced positive results from the Phase 3 DETECT study regarding their product NexoBrid, which showed that over 90% of patients with deep thermal burns achieved complete eschar removal after treatment. The study compared NexoBrid with standard care and a placebo, indicating a significantly lower need for surgery and a faster recovery time for patients treated with NexoBrid. These findings contribute to the establishment of NexoBrid as a potential new standard in burn care, and the data supported its recent FDA approval for commercial use.
Read more →VCELVericel Announces U.S. Commercial Availability of NexoBrid (anacaulase-bcdb) for the Treatment of Severe Thermal Burns in Adults
Vericel Corporation has announced the U.S. commercial availability of NexoBrid (anacaulase-bcdb), a treatment for severe thermal burns aimed at improving eschar removal. This new product, which selectively targets eschar while preserving viable tissue, represents a shift in the standard of care and significantly expands Vericel's market potential. Each year, around 40,000 individuals are hospitalized for burn-related injuries in the U.S., with a notable portion requiring eschar removal. NexoBrid's application method allows for effective treatment of affected areas, potentially reducing patient trauma.
Read more →VCELVericel Corporation 64 Sidney Street Cambridge, MA 02139 T 617 588-5555 F 617 588-5554 www.vcel.com Vericel Announces U.S. Commercial Availability of NexoBrid (anacaulase-bcdb) for the Treatment of Severe Thermal Burns i
Vericel Corporation has announced the U.S. commercial launch of NexoBrid (anacaulase-bcdb), intended for eschar removal in adults with severe thermal burns. This product is expected to change the standard of care as it selectively targets eschar, preserving viable tissue and potentially reducing the need for skin grafting. The launch is anticipated to expand Vericel’s market presence significantly, addressing an estimated $300 million market segment. However, the safety and effectiveness of NexoBrid have yet to be fully established for certain conditions, necessitating caution in its use.
Read more →VCELVericel to Present at the Morgan Stanley Global Healthcare Conference
Vericel Corporation announced that its President and CEO, Nick Colangelo, will participate in a fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference on September 12, 2023. The session is set to take place at 7:30 a.m. ET and will be available via webcast on Vericel's Investor Relations website. Vericel is known for its advanced therapies in sports medicine and severe burn care.
Read more →VCELVericel Reports Second Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance
Vericel Corporation reported robust financial performance for Q2 2023, achieving record revenues of $45.9 million, a 24% increase from the previous year. Revenue for the MACI product line grew by 27%, while Epicel saw a 17% increase. The company has raised its full-year revenue guidance to $190-197 million due to strong operational momentum and promising prospects, including the expected commercial launch of an arthroscopic delivery program for MACI in 2024. Despite a net loss of $5 million, the ongoing cash flow and profitability trends remain positive.
Read more →VCELVericel to Report Second-Quarter 2023 Financial Results on August 2, 2023
Vericel Corporation has announced it will report its financial results for the second quarter of 2023 on August 2, 2023. Management will conduct a conference call and webcast to discuss the results and business highlights. The live event can be accessed via their Investor Relations website, with a replay available until August 2, 2024. Vericel continues to focus on advanced therapies for sports medicine and severe burn care, indicating steady operations.
Read more →VCELVericel Reports First Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance
Vericel Corporation reported strong financial results for the first quarter of 2023, with total revenue reaching $41 million, a 14% increase year-over-year. The company experienced significant growth in MACI revenue, which rose 32% to $34.2 million. Additionally, Vericel raised its full-year revenue guidance to a range of $184 to $192 million based on positive first-quarter performance. However, the company also recorded a net loss of $7.5 million and increased operating expenses, which may suggest challenges ahead.
Read more →VCELVericel to Report First-Quarter 2023 Financial Results on May 10, 2023
Vericel Corporation will report its first-quarter 2023 financial results on May 10, 2023. Following the announcement, management will host a conference call and webcast at 8:30 a.m. (ET) to discuss the results and highlight business developments. Investors can access the live webcast through the company’s Investor Relations website, and presentation slides will be provided. A replay of the webcast will be available until May 10, 2024.
Read more →VCELVericel to Present at the Canaccord Genuity Musculoskeletal Conference on Tuesday, March 7, 2023
Vericel Corporation will present at the Canaccord Genuity Musculoskeletal Conference on March 7, 2023, led by President and CEO Nick Colangelo. The presentation will focus on Vericel's advancements in sports medicine and severe burn care therapies. A webcast will be available for investors, ensuring accessibility to the presentation's content. Vericel is known for its innovative cell therapy products, including MACI® and Epicel®.
Read more →VCEL▲ +7.3%on this newsshared move
Vericel Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Full-Year 2023 Financial Guidance
Vericel Corporation reported strong financial results for the fourth quarter and full year 2022, achieving total revenues of $52.7 million in Q4 and $164.4 million for the year, despite facing a net loss of $16.7 million. The company saw significant growth in MACI product sales, with an expected revenue increase for 2023 to between $180 and $188 million. Furthermore, Vericel received FDA approval for NexoBrid, which is anticipated to launch later in 2023, and is planning to expand MACI's indications.
Read more →VCEL▲ +7.3%on this newsshared move
Vericel Corporation 64 Sidney Street Cambridge, MA 02139 T (617) 588-5555 F (617) 588-5554 www.vcel.com Vericel Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Full-Year 2023 Financial Guidance R
Vericel Corporation reported strong financial results for Q4 and full-year 2022, with record revenues and significant profit growth. Total revenue for Q4 was $52.7 million, marking an 11% increase from the previous year. The company expects 2023 revenue guidance to be between $180 million and $188 million, driven by sales of MACI and anticipated growth from new products. However, despite financial gains, Vericel reported a net loss for the entire year due to increased operating expenses.
Read more →VCELVericel to Report Fourth-Quarter 2022 Financial Results on February 23, 2023
Vericel Corporation has announced that it will report its fourth-quarter 2022 financial results on February 23, 2023. The event will include a conference call and webcast where management will provide insights on the financial outcomes and business highlights. Vericel specializes in advanced therapies for sports medicine and severe burn care, showcasing a commitment to innovative healthcare solutions.
Read more →VCEL▲ +16.3%on this news
Vericel Announces Preliminary Fourth-Quarter and Full-Year 2022 Financial Results and Accelerated Launch Timeline for MACI Arthroscopic Program Full-Year Total Revenue Expected to be Approximately $164 to $165 Million MA
Vericel Corporation (NASDAQ:VCEL) announced preliminary financial results for Q4 and full-year 2022, forecasting total revenue of approximately $164 to $165 million. The company experienced a strong fourth-quarter growth of about 24%. Additionally, the launch timeline for the MACI arthroscopic delivery program has been accelerated to 2024. However, the reported figures are preliminary and subject to change based on further audits.
Read more →VCELVericel to Present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023
Vericel Corporation has announced that its President and CEO, Nick Colangelo, will be presenting at the 41st Annual J.P. Morgan Healthcare Conference. The presentation is set to occur on January 11, 2023, at 10:30 a.m. ET. Investors can access a webcast of the presentation on the company's Investor Relations website. Vericel specializes in advanced therapies for sports medicine and severe burn care, highlighting its significant contributions to these fields.
Read more →VCEL▲ +5%on this newsshared move
Vericel Announces FDA Approval of NexoBrid for the Treatment of Severe Thermal Burns in Adults
Potential to become the new standard of care for eschar removal in patients with deep partial- and/or full- thickness thermal burns Label supported by robust clinical data demonstrating significantly higher incidence of complete eschar removal in patients treated with NexoBrid c
Read more →VCEL▲ +5%on this newsshared move
Vericel Corporation 64 Sidney Street Cambridge, MA 02139 T 617 588-5555 F 617 588-5554 www.vcel.com Vericel Announces FDA Approval of NexoBrid for the Treatment of Severe Thermal Burns in Adults Potential to become the n
Vericel Corporation 64 Sidney Street Cambridge, MA 02139 T 617 588-5555 F 617 588-5554 www.vcel.com Vericel Announces FDA Approval of NexoBrid for the Treatment of Severe Thermal Burns in Adults the new standard of care for eschar removal in patients with deep partial- and/or
Read more →VCEL▲ +27%on this news
Vericel to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health & Service Forum and the Stephens Annual Investment Conference
CAMBRIDGE, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Company leadership will present at the upcoming Canaccord Genuity MedTech, Diagnostics,
Read more →VCEL▼ -23.4%on this newsshared move
Vericel Reports Third Quarter 2022 Financial Results
Total Net Product Revenue of $38.6 Million MACI Net Revenue Increased 30% to $31.0 Million Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine
Read more →VCEL▼ -23.4%on this newsshared move
VERICEL CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited, amounts in thousands) September 30
Vericel Corporation 64 Sidney Street Cambridge, MA 02139 T (617) 588-5555 F (617) 588-5554 www.vcel.com Vericel Reports Third Quarter 2022 Financial Results Total Net Product Revenue of $38.6 Million MACI Net Revenue Increased 30% to $31.0 Million Conference Call Today at 8
Read more →VCELVericel to Report Third-Quarter 2022 Financial Results on November 9, 2022
CAMBRIDGE, Mass., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its third-quarter 2022 financial results on Wednesday, November 9, 2022.
Read more →VCELVericel to Present at the Ladenburg Thalmann Healthcare Conference
CAMBRIDGE, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Chief Financial Officer Joe Mara will present at the upcoming Ladenburg Thalmann Healt
Read more →VCELVericel to Present at the Morgan Stanley Global Healthcare and H.C. Wainwright Global Investment Conferences
CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Company leadership will present at the upcoming Morgan Stanley and H.C. Wainwright inv
Read more →VCELVERICEL CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited, amounts in thousands) June 30
Vericel Corporation 64 Sidney Street Cambridge, MA 02139 T (617) 588-5555 F (617) 588-5554 www.vcel.com Vericel Reports Second Quarter 2022 Financial Results Second Quarter Total Net Revenue of $37.0 Million MACI Net Revenue of $28.6 Million Conference Call Today at 8 30am E
Read more →VCELVericel Reports Second Quarter 2022 Financial Results
Second Quarter Total Net Revenue of $37.0 Million MACI Net Revenue of $28.6 Million Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and se
Read more →VCELVericel Announces Publication of Positive Results from Retrospective Study by the Burn and Reconstructive Centers of America (BRCA) of Patients with Large Posterior Trunk Burns Treated with Epicel
Data published in the Journal of Burn Care & Research show 83% of patients with posterior burns (mean total body surface area of 56%) had successful engraftment of Epicel after one or two applications 90% survival rate following Epicel and/or Epicel plus split thickness skin gra
Read more →VCELVericel to Report Second-Quarter 2022 Financial Results on August 3, 2022
CAMBRIDGE, Mass., July 20, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its second-quarter 2022 financial results on Wednesday, August 3, 2022.
Read more →VCELVERICEL CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited, amounts in thousands) March 31
Vericel Corporation 64 Sidney Street Cambridge, MA 02139 T (617) 588-5555 F (617) 588-5554 www.vcel.com Vericel Reports First Quarter 2022 Financial Results First Quarter Total Net Revenue of $36.1 Million Conference Call Today at 8 30am Eastern Time CAMBRIDGE, Mass., May 4,
Read more →VCELVericel Reports First Quarter 2022 Financial Results
First Quarter Total Net Revenue of $36.1 Million Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reporte
Read more →VCELVericel to Report First-Quarter 2022 Financial Results on May 4, 2022
CAMBRIDGE, Mass., April 20, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its first-quarter 2022 financial resul
Read more →VCELVericel to Present at the Canaccord Genuity Musculoskeletal Conference on March 22, 2022
CAMBRIDGE, Mass., March 15, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will present at the Canaccord Genuity Musculoskelet
Read more →VCELVericel to Present at the Cowen 42nd Annual Health Care Conference on March 9, 2022
CAMBRIDGE, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will participate in a fireside chat at the Cowen 42
Read more →VCEL▲ +20.8%on this newsshared move
Vericel Corporation 64 Sidney Street Cambridge, MA 02139 T 617 588-5555 F 617 588-5554 www.vcel.com Vericel Announces Appointment of Jonathan Siegal as Principal Accounting Officer
Announces Appointment of Jonathan Siegal as Principal Accounting Officer CAMBRIDGE, Mass., February 24, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Boa
Read more →VCEL▲ +20.8%on this newsshared move
Vericel Announces Appointment of Jonathan Siegal as Principal Accounting Officer
CAMBRIDGE, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Board of Directors has appointed Jonathan Siegal as the Company’s Principal Account
Read more →VCEL▲ +20.8%on this newsshared move
Vericel Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Full-Year 2022 Financial Guidance
Full-Year 2021 Total Revenue Growth of 26% Full-Year 2022 Total Revenue Guidance of $178 to $189 Million Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the s
Read more →VCELVericel to Report Fourth-Quarter 2021 Financial Results on February 24, 2022
CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its fourth-quarter 2021 financial resul
Read more →VCELVericel Announces Plans for a New State-of-the-Art Cell Therapy Manufacturing Facility to Support Long-Term Growth
CAMBRIDGE, Mass., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it has entered into a long-term lease agreement for a new state-of-the-art advanced cel
Read more →VCELVericel to Present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022
CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will present at the 40th Annual J.P. Morgan Healthca
Read more →VCELAdvanced Therapies for the Sports Medicine and Severe Burn Care Markets CORPORATE PRESENTATION JANUARY 2022 Safe Harbor 2 Vericel has provided in this presentation certain financial information that has not been prepared
Building a Pipeline Through Current Portfolio and Business Development 20 PRODUCT INDICATION/STUDY PRECLINICAL PHASE I PHASE II PHASE III REGISTRATION APPROVAL Treatment of Symptomatic Cartilage Defects of the Knee in Adults Pediatric (PEAK) Study Knee Arthroscopic Delivery Knee
Read more →VCELVericel to Present at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health and Services Forum on November 18th, 2021
CAMBRIDGE, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will present at the Canaccord Genuity Virtual MedTec
Read more →VCELRECONCILIATION OF REPORTED NET INCOME (LOSS) (GAAP) TO ADJUSTED EBITDA (NON-GAAP MEASURE) - UNAUDITED Three Months Ended September 30, Nine Months Ended September 30, (In thousands) 2021 2020 2021 2020 Net income (loss)
Vericel Reports Third Quarter 2021 Financial Results Third Quarter Total Net Revenue of $34.5 Million Year-To-Date 2021 Revenue Increased 38% to $108.6 Million Conference Call Today at 8 30am Eastern Time CAMBRIDGE, Mass., November 9, 2021 (GLOBE NEWSWIRE) - Vericel Corporati
Read more →VCELVericel Reports Third Quarter 2021 Financial Results
Third Quarter Total Net Revenue of $34.5 Million Year-To-Date 2021 Revenue Increased 38% to $108.6 Million Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the
Read more →VCELVericel to Report Third-Quarter 2021 Financial Results on November 9, 2021
CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its third-quarter 2021 financial result
Read more →VCELVericel to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference on September 13th, 2021
CAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will participate in a virtual fireside chat at the
Read more →VCELVericel Expands Executive Leadership Team and Announces Appointment of Patrick Fowler as Senior Vice President, Corporate Development and Strategy
CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, announced the appointment of Patrick J. Fowler as Senior Vice President, Corporate Development and Strategy
Read more →VCELVericel Reports Second Quarter 2021 Financial Results and Raises Full-Year 2021 Revenue Guidance
Second Quarter Total Net Revenue Increased 97% to $39.5 Million Full-Year 2021 Revenue Guidance Raised to $168-$171 Million Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced
Read more →VCELVericel Corporation 64 Sidney Street Cambridge, MA 02139 T (617) 588-5555 F (617) 588-5554 www.vcel.com Vericel Reports Second Quarter 2021 Financial Results and Raises Full-Year 2021 Revenue Guidance Second Quarter Tota
Vericel Reports Second Quarter 2021 Financial Results and Raises Full-Year 2021 Revenue Guidance Second Quarter Total Net Revenue Increased 97% to $39.5 Million Full-Year 2021 Revenue Guidance Raised to $168-$171 Million Conference Call Today at 8 30am Eastern Time CAMBRIDGE,
Read more →VCELVericel Corporation Investors: Company Investigated by the Portnoy Law Firm
LOS ANGELES, July 22, 2021 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Vericel Corporation ("Vericel" or the "Company") (NASDAQ: VCEL) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors.
Read more →VCELVericel to Report Second-Quarter 2021 Financial Results on August 4, 2021
CAMBRIDGE, Mass., July 21, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its second-quarter 2021 financial resul
Read more →VCELVericel to Present at the Ladenburg Thalmann Healthcare Conference on Tuesday, July 13, 2021
CAMBRIDGE, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will present the latest company overview at the Lade
Read more →VCELVericel Provides Regulatory Update for NexoBrid
CAMBRIDGE, Mass., June 29, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that its development partner, MediWound Ltd., received a complete response letter (CRL) from
Read more →VCELVericel Corporation 64 Sidney Street Cambridge, MA 02139 T 617 588-5555 F 617 588-5554 www.vcel.com Vericel Provides Regulatory Update for NexoBrid
Vericel Provides Regulatory CAMBRIDGE, Mass., June 29, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that its development partner, MediWound Ltd., received a comp
Read more →VCELVericel to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference on Thursday, June 10, 2021
CAMBRIDGE, Mass., June 09, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will present the latest company overview at the Gold
Read more →VCELVericel Announces Appointment of Lisa Wright to Board of Directors
CAMBRIDGE, Mass., June 02, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the appointment of Lisa Wright to its Board of Directors, effective immediately. Ms. Wright
Read more →VCELVericel Corporation 64 Sidney Street Cambridge, MA 02139 T 617 588-5555 F 617 588-5554 www.vcel.com Vericel Announces Appointment of Lisa Wright to Board of Directors
Vericel Corporation 64 Sidney Street Cambridge, MA 02139 T 617 588-5555 F 617 588-5554 www.vcel.com Vericel Announces Appointment of Lisa Wright to Board of Directors CAMBRIDGE, Mass., June 2, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced t
Read more →VCELVericel to Present at the Canaccord Genuity Virtual Musculoskeletal Conference on Thursday, May 20, 2021
CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will present the latest company overview at the Canac
Read more →VCELVericel Reports First Quarter 2021 Financial Results and Raises Full-Year 2021 Revenue Guidance
First Quarter Total Net Revenue Increased 30% to $34.6 Million Full-Year 2021 Revenue Guidance Raised to $165-$168 Million Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced th
Read more →VCELVericel Corporation 64 Sidney Street Cambridge, MA 02139 T (617) 588-5555 F (617) 588-5554 www.vcel.com Vericel Reports First Quarter 2021 Financial Results and Raises Full-Year 2021 Revenue Guidance First Quarter Total
Vericel Reports First Quarter 2021 Financial Results and Raises Full-Year 2021 Revenue Guidance First Quarter Total Net Revenue Increased 30% to $34.6 Million Full-Year 2021 Revenue Guidance Raised to $165 - $168 Million Conference Call Today at 8 30am Eastern Time CAMBRIDGE,
Read more →VCELVericel to Report First-Quarter 2021 Financial Results on May 5, 2021
CAMBRIDGE, Mass., April 21, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its first-quarter 2021 financial resul
Read more →VCELVericel to Present at the 20th Annual Needham Virtual Healthcare Conference on Thursday, April 15, 2021
CAMBRIDGE, Mass., April 09, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will present the latest company overview at the 20t
Read more →VCELVericel to Present at the Oppenheimer 31st Annual Healthcare Conference on Wednesday, March 17, 2021
CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will present the latest company overview at the Opp
Read more →VCELVericel Announces Webcast of Presentation at Upcoming H.C. Wainwright Virtual Global Life Sciences Conference
CAMBRIDGE, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Joe Mara, Chief Financial Officer, will present the latest company overview at the H.C
Read more →VCELVericel Reports Fourth Quarter and Full-Year 2020 Financial Results and Provides Full-Year 2021 Financial Guidance
Record Fourth Quarter Total Revenue, Gross Margin, Net Income and Operating Cash Flow Full-Year 2021 Total Revenue Expected to Grow 30%-32% to Approximately $161 to $164 Million Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Ve
Read more →VCELVericel Corporation 64 Sidney Street Cambridge, MA 02139 T (617) 588-5555 F (617) 588-5554 www.vcel.com Vericel Reports Fourth Quarter and Full-Year 2020 Financial Results and Provides Full-Year 2021 Financial Guidance R
Vericel Reports Fourth Quarter and Full-Year 2020 Financial Results and Provides Full-Year 2021 Financial Guidance Record Fourth Quarter Total Revenue, Gross Margin, Net Income and Operating Cash Flow Full-Year 2021 Total Revenue Expected to Grow 30%-32% to Approximately $161 t
Read more →VCELVericel to Present at the SVB Leerink 10th Annual Global Healthcare Conference on Thursday, February 25, 2021
CAMBRIDGE, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will present the latest company overview at the SVB
Read more →VCELVericel to Participate in the BTIG Virtual MedTech Digital Health, Life Science & Diagnostic Tools Conference on February 18, 2021
CAMBRIDGE, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, and Joe Mara, CFO, will participate in a fireside ch
Read more →VCELVericel Corporation 64 Sidney Street Cambridge, MA 02139 T 617 588-5555 F 617 588-5554 www.vcel.com Vericel Announces Termination of Shareholder Rights Agreement
Announces Termination of Shareholder Rights Agreement CAMBRIDGE, Mass., February 12, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that its Board of Directors una
Read more →VCELVericel Announces Termination of Shareholder Rights Agreement
CAMBRIDGE, Mass., Feb. 12, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that its Board of Directors unanimously approved the termination of the Company’s shareholde
Read more →VCELVericel to Report Fourth-Quarter 2020 Financial Results on February 24, 2021
CAMBRIDGE, Mass., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its fourth-quarter 2020 financial resul
Read more →VCELVericel Corporation 64 Sidney Street Cambridge, MA 02139 T 617 588-5555 F 617 588-5554 www.vcel.com Vericel Announces Appointment of Joe Mara as Chief Financial Officer
Vericel Corporation 64 Sidney Street Cambridge, MA 02139 T 617 588-5555 F 617 588-5554 www.vcel.com Announces Appointment of Joe Mara as Chief Financial Officer CAMBRIDGE, Mass., January 25, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced ther
Read more →VCELVericel Announces Appointment of Joe Mara as Chief Financial Officer
CAMBRIDGE, Mass., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, announced the appointment of Joe Mara as Chief Financial Officer of the Company, effective today. Mr. Mara
Read more →VCELVericel Corporation 64 Sidney Street Cambridge, MA 02139 T 617 588-5555 F 617 588-5554 www.vcel.com Vericel Announces Preliminary Fourth-Quarter and Full-Year 2020 Financial Results and Provides Business Updates Record Q
Preliminary Fourth-Quarter and Full-Year 2020 Financial Results and Provides Business Updates Record Quarterly and Full-Year Total Fourth Quarter Revenue Growth of Approximately CAMBRIDGE, Mass., January 11, 2021 (GLOBE NEWSWIRE) - Vericel Corporation (NASDAQ:VCEL), a leader
Read more →VCELVericel Announces Preliminary Fourth-Quarter and Full-Year 2020 Financial Results and Provides Business Updates
Record Quarterly and Full-Year Total Revenues Fourth Quarter Revenue Growth of Approximately 15% CAMBRIDGE, Mass., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today ann
Read more →VCELVericel to Present at the 23rd Annual Needham Growth Conference on Friday, January 15, 2021
CAMBRIDGE, Mass., Jan. 08, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will present the latest company overview at the 23rd
Read more →VCELVericel Announces Expansion of MACI Coverage by UnitedHealthcare to Include Patella and Multiple Cartilage Defects in the Knee
CAMBRIDGE, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that UnitedHealthcare has expanded its medical policy for MACI® (autologous cultured chondro
Read more →VCELVericel to Present at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2021
CAMBRIDGE, Mass., Dec. 18, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will present the latest company overview at the 39th
Read more →VCELVericel Reports Record Third Quarter Revenues and Net Income
Total Net Revenues of $32.3 Million and Net Income of $3.6 Million Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care ma
Read more →VCELVericel Corporation 64 Sidney Street Cambridge, MA 02139 T (617) 588-5555 F (617) 588-5554 www.vcel.com Vericel Reports Record Third Quarter Revenues and Net Income Total Net Revenues of $32.3 Million and Net Income of $
Vericel Reports Record Third Quarter Revenues and Net Income Total Net Revenues of $32.3 Million and Net Income of $3.6 Million Conference Call Today at 8 30am Eastern Time CAMBRIDGE, Mass., November 5, 2020 (GLOBE NEWSWIRE) - Vericel Corporation (NASDAQ VCEL), a leader in adv
Read more →VCELVericel to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced presentations at the following upcoming investor conferences. The Credit Suisse 29th Annual
Read more →VCELVericel to Report Third-Quarter 2020 Financial Results on November 5, 2020
CAMBRIDGE, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its third-quarter 2020 financial result
Read more →VCELVericel Announces Preliminary Third Quarter 2020 Total Net Revenues of $32 Million
Double-Digit Revenue, Implant and Biopsy Growth for MACI in the Quarter and Record Monthly Biopsies in September Approximately $4.6 Million of Operating Cash Flow for the Quarter CAMBRIDGE, Mass., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in
Read more →VCELVericel Corporation 64 Sidney Street Cambridge, MA 02139 T 617 588-5555 F 617 588-5554 www.vcel.com Vericel Announces Preliminary Third Quarter 2020 Total Net Revenues of $32 Million Double-Digit Revenue, Implant and Bio
Announces Preliminary Third Quarter 2020 Total Net Revenues of $32 Million Double-Digit Revenue, Implant and Biopsy Growth for MACI in the Quarter and Record Monthly Biopsies in September Approximately $4.6 Million of Operating Cash Flow for the Quarter CAMBRIDGE, Mass., Oct
Read more →VCELVericel To Host Virtual Analyst and Investor Day on October 16, 2020
CAMBRIDGE, Mass., Oct. 09, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, will host a virtual Analyst and Investor Day on Friday, October 16, 2020, from 9:00 a.m. - 11:00 a.m. ET. Du
Read more →VCELVericel Announces FDA Acceptance of Biologics License Application for NexoBrid for the Treatment of Severe Thermal Burns
CAMBRIDGE, Mass., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ: VCEL) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the recently submitted Biologics License Application (BLA) for NexoBrid® (concentrate of proteolytic en
Read more →VCELVericel Corporation 64 Sidney Street Cambridge, MA 02139 T 617 588-5555 F 617 588-5554 www.vcel.com Vericel Announces FDA Acceptance of Biologics License Application for NexoBrid for the Treatment of Severe Thermal Burns
Vericel Corporation 64 Sidney Street Cambridge, MA 02139 T 617 588-5555 F 617 588-5554 www.vcel.com Announces FDA Acceptance of Biologics License Application for NexoBrid for the Treatment of Severe Thermal Burns CAMBRIDGE, Mass., September 16, 2020 (GLOBE NEWSWIRE) -- Vericel
Read more →VCELVericel to Present at the 18th Annual Morgan Stanley Global Healthcare Conference on Thursday, September 17, 2020
CAMBRIDGE, Mass., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will present the latest company overview at the 18t
Read more →VCELVericel Reports Second Quarter 2020 Financial Results
Product Revenues of $20.0 Million Reported for the Second Quarter Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care mark
Read more →VCELVericel Corporation 64 Sidney Street Cambridge, MA 02139 T (617) 588-5555 F (617) 588-5554 www.vcel.com Vericel Reports Second Quarter 2020 Financial Results Product Revenues of $20.0 Million Reported for the Second Quar
Vericel Reports Second Quarter 2020 Financial Results Product Revenues of $20.0 Million Reported for the Second Quarter Conference Call Today at 8 30am Eastern Time CAMBRIDGE, Mass., August 5, 2020 (GLOBE NEWSWIRE) - Vericel Corporation (NASDAQ VCEL), a leader in advanced ther
Read more →VCELVericel to Report Second-Quarter 2020 Financial Results on August 5, 2020
CAMBRIDGE, Mass., July 22, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its second-quarter 2020 financial resul
Read more →VCELVericel Announces Preliminary Second Quarter 2020 Financial Results and Provides Business Updates
CAMBRIDGE, Mass., July 09, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced preliminary financial results for the quarter ended June 30, 2020, and provided business upd
Read more →VCELVericel Corporation 64 Sidney Street Cambridge, MA 02139 T 617 588-5555 F 617 588-5554 www.vcel.com Vericel Announces Preliminary Second Quarter 2020 Financial Results and Provides Business Updates Second Quarter Net Pro
Announces Preliminary Second Quarter 2020 Financial Results and Provides Business Updates Quarter Net Product Revenues Expected to be Approximately $20 Million July 9, 2020 (GLOBE NEWSWIRE) - Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medi
Read more →VCELVericel Announces Submission of Biologics License Application to the FDA for NexoBrid for the Treatment of Severe Thermal Burns
Announces Submission of Biologics License Application to the FDA for NexoBrid for the Treatment of Severe Thermal Burns CAMBRIDGE, Mass., June 30, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ: VCEL) today announced the submission of a Biologics License Application (BLA)
Read more →VCELVericel to Present at the UBS Virtual Global Healthcare Conference on Wednesday, May 20, 2020
CAMBRIDGE, Mass., May 13, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, president and CEO, will present the latest company overview at the UBS V
Read more →VCELVericel Corporation 64 Sidney Street Cambridge, MA 02139 T (617) 588-5555 F (617) 588-5554 www.vcel.com Vericel Reports First Quarter 2020 Financial Results Product Revenues of $26.7 Million Increase 22% Over First Quart
Vericel Reports First Quarter 2020 Financial Results Product Revenues of $26.7 Million Increase 22% Over First Quarter 2019 Positive Cash Flow for the Quarter Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., May 5, 2020 (GLOBE NEWSWIRE) - Vericel Corporation (NA
Read more →VCELVericel Reports First Quarter 2020 Financial Results
Product Revenues of $26.7 Million Increase 22% Over First Quarter 2019 Positive Cash Flow for the Quarter Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., May 05, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the s
Read more →VCELVericel to Report First-Quarter 2020 Financial Results on May 5, 2020
CAMBRIDGE, Mass., April 22, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its first-quarter 2020 financial resul
Read more →VCELVericel Announces Change to a Virtual Meeting Format For 2020 Annual Meeting of Shareholders
CAMBRIDGE, Mass., April 10, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that as a result of the COVID-19 pandemic, to support the health and well-being of our empl
Read more →VCELVericel to Present at the 19th Annual Needham Healthcare Conference on Tuesday, April 14, 2020
CAMBRIDGE, Mass., April 08, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, president and CEO, will present the latest company overview at the 19t
Read more →VCELVericel Corporation 64 Sidney Street Cambridge, MA 02139 T 617 588-5555 F 617 588-5554 www.vcel.com Vericel Provides Business and Financial Updates First Quarter Preliminary Unaudited Product Revenues Increased Approxima
Provides Business and Financial Updates Preliminary Unaudited Product Revenues Increased Approximately 21% Over First Quarter 2019 Financial Guidance Withdrawn Due to Uncertainty Regarding Impact of COVID-19 CAMBRIDGE, Mass., April 2, 2020 (GLOBE NEWSWIRE) - Vericel Corporati
Read more →VCELVericel Provides Business and Financial Updates
First Quarter Preliminary Unaudited Product Revenues Increased Approximately 21% Over First Quarter 2019 Full Year 2020 Financial Guidance Withdrawn Due to Uncertainty Regarding Impact of COVID-19 CAMBRIDGE, Mass., April 02, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:
Read more →VCELVericel Corporation 64 Sidney Street Cambridge, MA 02139 T (617) 588-5555 F (617) 588-5554 www.vcel.com Vericel Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Full-Year 2020 Financial Guidance F
Vericel Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Full-Year 2020 Financial Guidance Full Year 2019 Product Revenues of $117.9 Million Increased 30% Over 2018 Record Quarterly Revenue and Profit in the Fourth Quarter Conference Call Today at 8:30a
Read more →VCELVericel Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Full-Year 2020 Financial Guidance
Full Year 2019 Product Revenues of $117.9 Million Increased 30% Over 2018 Record Quarterly Revenue and Profit in the Fourth Quarter Conference Call Today at 8:30am Eastern Standard Time CAMBRIDGE, Mass., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a le
Read more →VCELVericel to Present at the 40th Annual Cowen Healthcare Conference on Monday, March 2, 2020
CAMBRIDGE, Mass., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, president and CEO, will present the latest company overview at the 40th
Read more →VCELVericel to Present at the 9th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 26, 2020
CAMBRIDGE, Mass., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, president and CEO, will present the latest company overview at the 9th
Read more →VCELVericel to Report Fourth-Quarter 2019 Financial Results on February 25, 2020
CAMBRIDGE, Mass., Feb. 11, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its fourth-quarter 2019 financial resul
Read more →VCELVericel to Present at the 22nd Annual Needham Growth Conference on Wednesday, January 15, 2020
CAMBRIDGE, Mass., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Gerard Michel, CFO, will present a company overview at the 22nd Annual Needham Growth C
Read more →VCELVericel Announces Appointment of Sean C. Flynn as Vice President and General Counsel
CAMBRIDGE, Mass., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the appointment of Sean C. Flynn as Vice President and General Counsel. Mr. Flynn has serve
Read more →VCELVericel Reports Record Third Quarter Revenues, Net Income and Operating Cash Flow
Product Revenues of $30.5 Million Increase 36% Over Third Quarter 2018 Full Year 2019 Revenue Guidance Raised to $116 to $118 Million Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in
Read more →VCELVericel Corporation 64 Sidney Street Cambridge, MA 02139 T (617) 588-5555 F (617) 588-5554 www.vcel.com Vericel Reports Record Third Quarter Revenues, Net Income and Operating Cash Flow Product Revenues of $30.5 Million
Vericel Reports Record Third Quarter Revenues, Net Income and Operating Cash Flow Product Revenues of $30.5 Million Increase 36% Over Third Quarter 2018 Full Year 2019 Revenue Guidance Raised to $116 to $118 Million Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass
Read more →VCELVericel to Report Third-Quarter 2019 Financial Results on November 5, 2019
CAMBRIDGE, Mass., Oct. 22, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its third-quarter 2019 financial result
Read more →VCELVericel and MediWound Announce Initiation of U.S. NexoBrid Expanded Access Treatment Protocol
CAMBRIDGE, Mass. and YAVNE, Israel, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ: VCEL) and MediWound Ltd. (NASDAQ: MDWD) today announced initiation of the NexoBrid® expanded access treatment protocol (NEXT) to treat burn patients with deep partial- and full-thic
Read more →VCELVericel to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference on Friday, October 4, 2019
CAMBRIDGE, Mass., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, president and CEO, will present the latest company overview at the 201
Read more →VCELVericel to Present at the Ladenburg Thalmann 2019 Healthcare Conference on Tuesday, September 24, 2019
CAMBRIDGE, Mass., Sept. 18, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Gerard Michel, CFO & VP of Corporate Development, will present the latest company over
Read more →VCELVericel to Present at the 17th Annual Morgan Stanley Global Healthcare Conference on Wednesday, September 11, 2019
CAMBRIDGE, Mass., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, president and CEO, will present the latest company overview at the 17t
Read more →VCELVericel Corporation 64 Sidney Street Cambridge, MA 02139 T (617) 588-5555 F (617) 588-5554 www.vcel.com Vericel Reports Second Quarter 2019 Financial Results and Raises Full Year 2019 Revenue Guidance Record Second Quart
Vericel Reports Second Quarter 2019 Financial Results and Raises Full Year 2019 Revenue Guidance Record Second Quarter Product Revenues of $26.2 Million Represent a 38% Increase Over Second Quarter 2018 Full Year 2019 Revenue Guidance Raised to $112 to $116 Million Conference
Read more →VCELVericel Reports Second Quarter 2019 Financial Results and Raises Full Year 2019 Revenue Guidance
Record Second Quarter Product Revenues of $26.2 Million Represent a 38% Increase Over Second Quarter 2018 Full Year 2019 Revenue Guidance Raised to $112 to $116 Million Conference Call Today at 8:00am Eastern Time CAMBRIDGE, Mass., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Vericel Cor
Read more →VCELVericel to Present at the 39th Annual Canaccord Genuity Growth Conference on Thursday, August 8, 2019
CAMBRIDGE, Mass., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, president and CEO, will present the latest company overview at the 39th
Read more →VCELVericel to Report Second-Quarter 2019 Financial Results on August 6, 2019
CAMBRIDGE, Mass., July 23, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its second-quarter 2019 financial
Read more →VCELVericel to Present at the 2019 UBS Global Healthcare Conference on Wednesday, May 22, 2019
CAMBRIDGE, Mass., May 15, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, president and CEO, will present the latest company overview at the
Read more →VCELVericel Corporation 64 Sidney Street Cambridge, MA 02139 T (617) 588-5555 F (617) 588-5554 www.vcel.com Vericel Reports First Quarter 2019 Financial Results and Raises Full Year 2019 Revenue Guidance MACI Revenue Increas
Exhibit 99.1 Vericel Corporation 64 Sidney Street Cambridge, MA 02139 T (617) 588-5555 F (617) 588-5554 www.vcel.com Vericel Reports First Quarter 2019 Financial Results and Raises Full Year 2019 Revenue Guidance MACI Revenue Increased 38% Over First Quarter 2018 Positiv
Read more →VCELVericel Enters into Exclusive License Agreement with MediWound for North American Rights to NexoBrid, a Biological Orphan Product for Debridement of Severe Thermal Burns
Pivotal U.S. Phase 3 Clinical Study Met Primary and All Secondary Endpoints Highly Synergistic with Existing Commercial Franchise and Significantly Expands Vericel’s Presence in the Severe Burn Care Market CAMBRIDGE, Mass., May 07, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (
Read more →VCELVericel Reports First Quarter 2019 Financial Results and Raises Full Year 2019 Revenue Guidance
MACI Revenue Increased 38% Over First Quarter 2018 Positive Cash Flow in First Quarter Announced Exclusive License Agreement with MediWound for North American Rights to NexoBrid Conference Call Today at 8:00am Eastern Time CAMBRIDGE, Mass., May 07, 2019 (GLOBE NEWSWIRE) -- Ve
Read more →VCELVericel to Report First-Quarter 2019 Financial Results on May 7, 2019
CAMBRIDGE, Mass., April 25, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its first-quarter 2019 financial
Read more →VCELVericel to Present at Needham Healthcare Conference
CAMBRIDGE, Mass., April 03, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, president and CEO, will present the latest company overview at th
Read more →VCELVericel Corporation 64 Sidney Street Cambridge, MA 02139 T (617) 588-5555 F (617) 588-5554 www.vcel.com Vericel Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Full-Year 2019 Financial Guidance R
Exhibit 99.1 Vericel Corporation 64 Sidney Street Cambridge, MA 02139 T (617) 588-5555 F (617) 588-5554 www.vcel.com Vericel Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Full-Year 2019 Financial Guidance Record Quarterly Product Revenues of $31
Read more →VCELVericel Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Full-Year 2019 Financial Guidance
Record Quarterly Product Revenues of $31.3 Million Represent a 41% Increase Over Fourth Quarter 2017 Full-Year 2018 Product Revenues of $90.9 Million Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Feb. 26, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VC
Read more →VCELVericel to Participate in Multiple Upcoming Investor Conferences
CAMBRIDGE, Mass., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced participation in multiple upcoming investor conferences. Nick Colangelo, president and
Read more →VCELVericel to Report Fourth-Quarter 2018 Financial Results on February 26, 2019
CAMBRIDGE, Mass., Feb. 12, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its fourth-quarter 2018 financial
Read more →VCELVericel to Present at the 21st Annual Needham Growth Conference
CAMBRIDGE, Mass., Jan. 11, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, president and CEO, will present the latest company overview at the
Read more →VCELVericel Reports Publication of Outcomes Data From 954 Burn Patients Treated With Epicel in the Journal of Burn Care and Research
CAMBRIDGE, Mass., Jan. 04, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced the publication of outcomes data for 954 burn patients treated with Epicel® (cultured e
Read more →VCELVericel Corporation 64 Sidney Street Cambridge, MA 02139 T (617) 252-7999 F (617) 252-7550 www.vcel.com Vericel Reports Record Third Quarter Revenues of $22.5 Million and Raises Full Year 2018 Revenue Guidance 58% Revenu
Exhibit 99.1 Vericel Corporation 64 Sidney Street Cambridge, MA 02139 T (617) 252-7999 F (617) 252-7550 www.vcel.com Vericel Reports Record Third Quarter Revenues of $22.5 Million and Raises Full Year 2018 Revenue Guidance 58% Revenue Growth Over Third Quarter 2017 Confe
Read more →VCELVericel Reports Record Third Quarter Revenues of $22.5 Million and Raises Full Year 2018 Revenue Guidance
58% Revenue Growth Over Third Quarter 2017 Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today reporte
Read more →VCELVericel to Present at the Canaccord Genuity Medical Technologies & Diagnostic Forum
CAMBRIDGE, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, president and CEO, will present the latest company overview at the
Read more →VCELVericel to Report Third-Quarter 2018 Financial Results on November 6, 2018
CAMBRIDGE, Mass., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its third-quarter 2018 financial r
Read more →VCELVericel to Present at Multiple Upcoming Conferences
CAMBRIDGE, Mass., Sept. 21, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, will be presenting at the following investor and industry conferences: Nick Colangelo, president and
Read more →VCELVericel Announces Appointment of Jonathan Hopper as Chief Medical Officer
CAMBRIDGE, Mass., Aug. 20, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced the appointment of Jonathan Hopper as Chief Medical Officer. Dr. Hopper formerly serve
Read more →VCELVericel Corporation 64 Sidney Street Cambridge, MA 02139 T (617) 252-7999 F (617) 252-7550 www.vcel.com Vericel Reports Record Second Quarter Revenues of $19.0 Million and Raises Full Year 2018 Revenue Guidance Conferenc
Exhibit 99.1 Vericel Corporation 64 Sidney Street Cambridge, MA 02139 T (617) 252-7999 F (617) 252-7550 www.vcel.com Vericel Reports Record Second Quarter Revenues of $19.0 Million and Raises Full Year 2018 Revenue Guidance Conference Call Today at 4:30pm Eastern Time CA
Read more →VCELVericel Reports Record Second Quarter Revenues of $19.0 Million and Raises Full Year 2018 Revenue Guidance
CAMBRIDGE, Mass., Aug. 06, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the second quarter ended June 30, 2018. S
Read more →VCELVericel to Present at the 38th Annual Canaccord Genuity Growth Conference
CAMBRIDGE, Mass., July 26, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, president and CEO, will present the latest company overview at the
Read more →VCELVericel to Report Second-Quarter 2018 Financial Results on August 6, 2018
CAMBRIDGE, Mass., July 23, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its second-quarter 2018 financial
Read more →VCELVericel Added to Russell 3000 Index
CAMBRIDGE, Mass., June 25, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that it has been added to the Russell 3000® Index as part of the annual Russell U.S. In
Read more →VCELVericel Corporation Announces Closing of $74.8 Million Public Offering and Full Exercise of The Underwriters’ Option to Purchase Additional Shares
CAMBRIDGE, Mass., June 05, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced the closing of its previously announced underwritten public offering of 5,750,000 share
Read more →VCELVericel Corporation Prices $65 Million Public Offering of Common Stock
CAMBRIDGE, Mass., May 31, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced the pricing of its previously announced underwritten public offering of 5,000,000 shares
Read more →VCELVericel Corporation 64 Sidney Street Cambridge, MA 02139 T 617 588-5555 F 617 588-5554 Vericel Corporation Announces Proposed Public Offering of Common Stock
Vericel Corporation 64 Sidney Street Cambridge, MA 02139 T 617 588-5555 F 617 588-5554 Vericel Corporation Announces Proposed Public Offering of Common Stock CAMBRIDGE, Mass., May 30, 2018 (GLOBE NEWSWIRE) Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies
Read more →VCELVericel Corporation Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass., May 30, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that it intends to offer and sell, subject to market and other conditions, 3,750,000 sha
Read more →VCELVericel to Present at the Jefferies 2018 Global Healthcare Conference
CAMBRIDGE, Mass., May 25, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, president and CEO, will present the latest company overview at the
Read more →VCELVericel Corporation 64 Sidney Street Cambridge, MA 02139 T (617) 252-7999 F (617) 252-7550 www.vcel.com Vericel Reports First Quarter 2018 Financial Results Record First Quarter Revenues of $18.0 Million Conference Call
Exhibit 99.1 Vericel Corporation 64 Sidney Street Cambridge, MA 02139 T (617) 252-7999 F (617) 252-7550 www.vcel.com Vericel Reports First Quarter 2018 Financial Results Record First Quarter Revenues of $18.0 Million Conference Call Today at 8:30am Eastern Time CAMBRIDG
Read more →VCELVericel Reports First Quarter 2018 Financial Results
Record First Quarter Revenues of $18.0 Million Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., May 08, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today repo
Read more →VCELVericel to Report First-Quarter 2018 Financial Results on May 8, 2018
CAMBRIDGE, Mass., April 24, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its first-quarter 2018 financial
Read more →VCELVericel to Present at the 6th Annual Cell & Gene Therapy Investor Day
CAMBRIDGE, Mass., April 10, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, president and CEO, will present the latest company overview at th
Read more →VCELVericel Reports Publication of Results from the Phase 3 SUMMIT Extension Study Demonstrating Sustained Clinical Benefit of MACI Out to Five Years
CAMBRIDGE, Mass., March 23, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced the publication of results from the MACI® (autologous cultured chondrocytes on porcine
Read more →VCELVericel to Present at the 17th Annual Needham Healthcare Conference
CAMBRIDGE, Mass., March 13, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, president and CEO, will present the latest company overview at th
Read more →VCELVericel to Host Analyst and Investor Day on April 11, 2018
CAMBRIDGE, Mass., March 12, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that it will host an Analyst and Investor Day on April 11, 2018 in New York City from
Read more →VCELVericel to Present at BioCentury’s 25th Annual Future Leaders in the Biotech Industry Conference
CAMBRIDGE, Mass., March 09, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Gerard Michel, chief financial officer and VP of corporate development, will pres
Read more →VCELVericel Reports Fourth Quarter and Year End 2017 Financial Results and Provides Full Year 2018 Financial Guidance
Record Quarterly Revenues of $23.4 Million Represent a 41% Increase Over Fourth Quarter 2016 Positive Operating and Net Income Reported for the Fourth Quarter Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., March 05, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation
Read more →VCELVericel Corporation 64 Sidney Street Cambridge, MA 02139 T (617) 252-7999 F (617) 252-7550 www.vcel.com Vericel Reports Fourth Quarter and Year End 2017 Financial Results and Provides Full Year 2018 Financial Guidance Re
Exhibit 99.1 Vericel Corporation 64 Sidney Street Cambridge, MA 02139 T (617) 252-7999 F (617) 252-7550 www.vcel.com Vericel Reports Fourth Quarter and Year End 2017 Financial Results and Provides Full Year 2018 Financial Guidance Record Quarterly Revenues of $23.4 Millio
Read more →VCELVericel to Present at the 13th Annual Canaccord Genuity Musculoskeletal Conference
CAMBRIDGE, Mass., Feb. 26, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, president and CEO, will present the latest company overview at the
Read more →VCELVericel to Report Fourth-Quarter and Full-Year 2017 Financial Results on March 5, 2018
CAMBRIDGE, Mass., Feb. 22, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its fourth-quarter and full-year 2
Read more →VCELVericel to Present at the BIO CEO & Investor Conference
CAMBRIDGE, Mass., Feb. 05, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, president and CEO, will present the latest company overview at the
Read more →VCELVericel to Present at the 7th Annual Leerink Partners Global Healthcare Conference
CAMBRIDGE, Mass., Feb. 01, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, president and CEO, will present the latest company overview at the
Read more →VCELVericel to Present at the 20th Annual Needham Growth Conference
CAMBRIDGE, Mass., Jan. 10, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions, today announced that Nick Colangelo, president and CEO, will presen
Read more →VCELCompany Presentation January 2018 Safe Harbor This presentation contains forward-looking statements, including, without limitation, statements concerning anticipated progress, objectives and expectations regarding profit
Company Presentation January 2018 Safe Harbor This presentation contains forward-looking statements, including, without limitation, statements concerning anticipated progress, objectives and expectations regarding profitability, growth in revenue and earnings per share, cash pay
Read more →VCELVericel Initiates Collaboration with Innovative Cellular Therapeutics
CAMBRIDGE, Mass. and SHANGHAI, China, Jan. 02, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions, today announced the initiation of its License A
Read more →VCELVericel Enters into Expanded $25 Million Debt Facilities with Silicon Valley
Vericel Enters into Expanded $25 Million Debt Facilities with Silicon Valley Bank and MidCap Financial to Support Accelerating MACI Uptake and Increased Epicel Usage Facilities Include a $15 Term Loan and $10 Million Revolving Line of Credit CAMBRIDGE, Mass., Dec. 07, 2017 (G
Read more →VCELVericel Enters into Expanded $25 Million Debt Facilities with Silicon Valley Bank and MidCap Financial to Support Accelerating MACI Uptake and Increased Epicel Usage
CAMBRIDGE, Mass., Dec. 07, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions, today announced that it entered into an expanded $15 million term l
Read more →VCELVericel to Present at 29th Annual Piper Jaffray Healthcare Conference
CAMBRIDGE, Mass., Nov. 16, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions, today announced that Nick Colangelo, president and CEO, will presen
Read more →VCELVericel Corporation 64 Sidney Street Cambridge, MA 02139 T (617) 252-7999 F (617) 252-7550 www.vcel.com Vericel Reports Third-Quarter 2017 Financial Results Record Third Quarter Revenue of $14.3 Million Represents a 30%
Exhibit 99.1 Vericel Corporation 64 Sidney Street Cambridge, MA 02139 T (617) 252-7999 F (617) 252-7550 www.vcel.com Vericel Reports Third-Quarter 2017 Financial Results Record Third Quarter Revenue of $14.3 Million Represents a 30% Increase Over Third Quarter 2016 Resul
Read more →VCELVericel Reports Third-Quarter 2017 Financial Results
Record Third Quarter Revenue of $14.3 Million Represents a 30% Increase Over Third Quarter 2016 Results Driven by Continued Momentum of MACI Uptake and Expanded Epicel Usage Conference Call Today at 8:00am Eastern Time CAMBRIDGE, Mass., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Veric
Read more →VCELVericel to Host Third-Quarter 2017 Earnings Webcast and Conference Call on November 7, 2017
CAMBRIDGE, Mass., Oct. 25, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of autologous expanded cell therapies for the treatment of patients with serious diseases and conditions, today announced the following webcast and conference call: What: V
Read more →VCELVericel Provides Business Updates at 2017 Cell & Gene Meeting on the Mesa
CAMBRIDGE, Mass., Oct. 05, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions, today provided a general business update during a previously announ
Read more →VCELVericel to Present at the 2017 Cell & Gene Meeting on the Mesa
CAMBRIDGE, Mass., Sept. 27, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions, today announced that Nick Colangelo, president and CEO, will prese
Read more →VCELVericel to Present at the Ladenburg Thalmann 2017 Healthcare Conference
CAMBRIDGE, Mass., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions, today announced that Nick Colangelo, president and CEO, will prese
Read more →VCELVericel Corporation 64 Sidney Street Cambridge, MA 02139 T (617) 252-7999 F (617) 252-7550 www.vcel.com Vericel Reports Second-Quarter 2017 Financial Results Revenue of $17.0 Million Represents a 32% Increase Over Second
Exhibit 99.1 Vericel Corporation 64 Sidney Street Cambridge, MA 02139 T (617) 252-7999 F (617) 252-7550 www.vcel.com Vericel Reports Second-Quarter 2017 Financial Results Revenue of $17.0 Million Represents a 32% Increase Over Second Quarter 2016 Results Driven by Moment
Read more →VCELVericel Reports Second-Quarter 2017 Financial Results
Revenue of $17.0 Million Represents a 32% Increase Over Second Quarter 2016 Results Driven by Momentum of MACI Uptake Following Launch Conference Call Today at 8:00am Eastern Time CAMBRIDGE, Mass., Aug. 09, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading
Read more →VCELVericel to Host Second-Quarter 2017 Earnings Webcast and Conference Call on August 9, 2017
CAMBRIDGE, Mass., July 26, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of autologous expanded cell therapies for the treatment of patients with serious diseases and conditions, today announced the following webcast and conference call: What: V
Read more →VCELVericel to Host Symposium on MACI Implant for Treating Articular Cartilage Defects in the Knee at AOSSM 2017 Annual Meeting
CAMBRIDGE, Mass., July 13, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions, announced today that the company is hosting a symposium on the MAC
Read more →VCELVericel Reports First-Quarter 2017 Financial Results
CAMBRIDGE, Mass., May 10, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of autologous expanded cell therapies for the treatment of patients with serious diseases and conditions, today reported financial results for the first quarter ended March 3
Read more →VCELVericel Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Ixmyelocel-T for the Treatment of Advanced Heart Failure Due to Ischemic Dilated Cardiomyopathy
CAMBRIDGE, Mass., May 10, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of autologous expanded cell therapies for the treatment of patients with serious diseases and conditions, today announced that the U.S. Food and Drug Administration (FDA) has
Read more →VCELVericel Corporation 64 Sidney Street Cambridge, MA 02139 T (617) 252-7999 F (617) 252-7550 www.vcel.com Vericel Reports First-Quarter 2017 Financial Results Conference Call Today at 8:00am Eastern Time
Exhibit 99.1 Vericel Corporation 64 Sidney Street Cambridge, MA 02139 T (617) 252-7999 F (617) 252-7550 www.vcel.com Vericel Reports First-Quarter 2017 Financial Results Conference Call Today at 8:00am Eastern Time CAMBRIDGE, Mass., May 10, 2017 (GLOBE NEWSWIRE) - Verice
Read more →VCELVericel Licenses Product Portfolio to Innovative Cellular Therapeutics for Distribution in China, South Korea, and other Countries in Southeast Asia CAMBRIDGE, MA and SHANGHAI, CHINA
Vericel Licenses Product Portfolio to Innovative Cellular Therapeutics for Distribution in China, South Korea, and other Countries in Southeast Asia CAMBRIDGE, MA and SHANGHAI, CHINA, May 10, 2017 (GLOBE NEWSWIRE) Vericel Corporation (Nasdaq:VCEL), a leading developer of expand
Read more →VCELVericel to Host First-Quarter 2017 Earnings Webcast and Conference Call on May 10, 2017
CAMBRIDGE, Mass., May 04, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of autologous expanded cell therapies for the treatment of patients with serious diseases and conditions, today announced the following webcast and conference call: What:
Read more →VCELVericel to Present at the 5th Annual Cell & Gene Therapy Investor Day
CAMBRIDGE, Mass., April 20, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions, today announced that Nick Colangelo, president and CEO, will prese
Read more →VCELVericel Announces Appointment of Michael Halpin as Senior Vice President, Quality and Regulatory Affairs
CAMBRIDGE, Mass., April 10, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions, today announced the appointment of Michael Halpin as senior vice p
Read more →VCELVericel to Present at the 16th Annual Needham Healthcare Conference
CAMBRIDGE, Mass., March 28, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions, today announced that Nick Colangelo, president and CEO, will prese
Read more →VCELVericel Corporation 64 Sidney Street Cambridge, MA 02139 T (617) 252-7999 F (617) 252-7550 www.vcel.com Vericel Reports Fourth-Quarter and Year-End 2016 Financial Results Record Revenues of $16.5 Million Reported for the
Exhibit 99.1 Vericel Corporation 64 Sidney Street Cambridge, MA 02139 T (617) 252-7999 F (617) 252-7550 www.vcel.com Vericel Reports Fourth-Quarter and Year-End 2016 Financial Results Record Revenues of $16.5 Million Reported for the Fourth Quarter Conference Call Today
Read more →VCELVericel Reports Fourth-Quarter and Year-End 2016 Financial Results
Record Revenues of $16.5 Million Reported for the Fourth Quarter Conference Call Today at 8:00am Eastern Time CAMBRIDGE, Mass., March 10, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for the treatment of p
Read more →VCELVericel to Host Fourth-Quarter 2016 Earnings Webcast and Conference Call on March 10, 2017
CAMBRIDGE, Mass., March 03, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of autologous expanded cell therapies for the treatment of patients with serious diseases and conditions, today announced the following webcast and conference call: What:
Read more →VCELVericel Receives FDA Fast Track Designation for Ixmyelocel-T, an Investigational Product for the Treatment of Patients with Advanced Heart Failure Due to Ischemic Dilated Cardiomyopathy
CAMBRIDGE, Mass., Feb. 21, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of autologous expanded cell therapies for the treatment of patients with serious diseases and conditions, today announced that the U.S. Food and Drug Administration (FDA) ha
Read more →VCELVericel Announces First MACI Implant in the United States for the Treatment of Symptomatic Cartilage Defects of the Knee
CAMBRIDGE, Mass., Feb. 01, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions, today announced the first implant of MACI® (autologous cultured cho
Read more →VCELVericel Corporation Announces Exercise of Underwriters’ Over-Allotment Option and Closing of $20 Million Offering of Common Stock
CAMBRIDGE, Mass., Dec. 21, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions, today announced that it has closed its previously announced underwr
Read more →VCELVericel Corporation 64 Sidney Street Cambridge, MA 02139 T 617 588-5555 F 617 588-5554 www.vcel.com Vericel Corporation Prices $17 Million Public Offering of Common Stock
Vericel Corporation 64 Sidney Street Cambridge, MA 02139 T 617 588-5555 F 617 588-5554 www.vcel.com Vericel Corporation Prices $17 Million Public Offering of Common Stock CAMBRIDGE, Mass., December 16, 2016 (GLOBE NEWSWIRE) Vericel Corporation (NASDAQ:VCEL), a leading dev
Read more →VCELVericel Corporation Prices $17 Million Public Offering of Common Stock
CAMBRIDGE, Mass., Dec. 16, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions, today announced the pricing of its previously announced underwritte
Read more →VCELVericel Corporation 64 Sidney Street Cambridge, MA 02139 T 617 588-5555 F 617 588-5554 www.vcel.com FDA Approves MACI for the Treatment of Symptomatic Cartilage Defects of the Knee in Adults First Tissue-Engineered Autol
FDA Approves MACI for the Treatment of Symptomatic Cartilage Defects of the Knee in Adults First Tissue-Engineered Autologous Cellularized Scaffold Product Approved by the FDA Conference Call Today at 9:00am Eastern Standard Time CAMBRIDGE, Mass., December 14, 2016 (GLOBE NEWS
Read more →VCELVericel to Present at 28th Annual Piper Jaffray Healthcare Conference
CAMBRIDGE, Mass., Nov. 22, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of autologous expanded cell therapies for the treatment of patients with serious diseases and conditions, today announced that Nick Colangelo, president and CEO, will presen
Read more →VCELVericel Corporation 64 Sidney Street Cambridge, MA 02139 T 617 588-5555 F 617 588-5554 www.vcel.com Additional Pre-Specified Secondary Results on the Reduction of Ventricular Arrhythmias Presented at AHA from Vericel s P
Additional Pre-Specified Secondary Results on the Reduction of Ventricular Arrhythmias Presented at AHA from Vericel s Positive Phase 2b ixCELL-DCM Clinical Trial of Ixmyelocel-T CAMBRIDGE, Mass., November 14, 2016 (GLOBE NEWSWIRE) Vericel Corporation (NASDAQ: VCEL), a leading d
Read more →VCELVericel Corporation 64 Sidney Street Cambridge, MA 02139 T (617) 252-7999 F (617) 252-7550 www.vcel.com Vericel Reports Third-Quarter 2016 Financial Results Total Revenues of $10.9 Million Reported for the Quarter Confer
Exhibit 99.1 Vericel Corporation 64 Sidney Street Cambridge, MA 02139 T (617) 252-7999 F (617) 252-7550 www.vcel.com Vericel Reports Third-Quarter 2016 Financial Results Total Revenues of $10.9 Million Reported for the Quarter Conference Call Today at 4:30pm Eastern Time
Read more →VCELVericel Reports Third-Quarter 2016 Financial Results
Total Revenues of $10.9 Million Reported for the Quarter Conference Call Today at 4:30pm Eastern Time CAMBRIDGE, Mass., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of autologous expanded cell therapies for the treatment of severe dis
Read more →VCELVericel to Host Third-Quarter 2016 Earnings Webcast and Conference Call on November 7, 2016
CAMBRIDGE, Mass., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of autologous expanded cellular therapies for the treatment of severe diseases and conditions, today announced the following webcast and conference call: What: Vericel Corp
Read more →VCELVericel to Present at 2016 Cell & Gene Meeting on the Mesa
CAMBRIDGE, Mass., Sept. 26, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of autologous cellular therapies for the treatment of severe diseases and conditions, today announced that Nick Colangelo, president and CEO, will present at the annual Cel
Read more →VCELVericel to Present at Ladenburg Thalmann Healthcare Conference
CAMBRIDGE, Mass., Sept. 21, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of autologous cellular therapies for the treatment of severe diseases and conditions, today announced that Nick Colangelo, president and CEO, and Gerard Michel, chief finan
Read more →VCELVericel Corporation 64 Sidney Street Cambridge, MA 02139 T 617 588-5555 F 617 588-5554 www.vcel.com Vericel Enters into Expanded $20 Million Credit Facility and Term Loan with Silicon Valley Bank and MidCap Financial Ser
Vericel Corporation 64 Sidney Street Cambridge, MA 02139 T 617 588-5555 F 617 588-5554 www.vcel.com Vericel Enters into Expanded $20 Million Credit Facility and Term Loan with Silicon Valley Bank and MidCap Financial Services CAMBRIDGE, Mass., September 12, 2016 (GLOBE NEWSWIR
Read more →VCELVericel Enters into Expanded $20 Million Credit Facility and Term Loan with Silicon Valley Bank and MidCap Financial Services
CAMBRIDGE, Mass., Sept. 12, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of autologous expanded cellular therapies for the treatment of severe diseases and conditions, announced today that it entered into an expanded term loan and revolving line
Read more →VCELVericel to Present Data at the American Heart Association’s Scientific Sessions 2016 on the Reduction of Ventricular Arrhythmias with Ixmyelocel-T in the ixCELL-DCM Clinical Trial
CAMBRIDGE, Mass., Sept. 07, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of autologous expanded cellular therapies for the treatment of severe diseases and conditions, today announced the acceptance of an abstract for presentation at the America
Read more →VCELVericel Corporation 64 Sidney Street Cambridge, MA 02139 T (617) 252-7999 F (617) 252-7550 www.vcel.com Vericel Reports Second-Quarter 2016 Financial Results Total Revenues of $12.8 Million Reported for the Quarter Confe
Exhibit 99.1 Vericel Corporation 64 Sidney Street Cambridge, MA 02139 T (617) 252-7999 F (617) 252-7550 www.vcel.com Vericel Reports Second-Quarter 2016 Financial Results Total Revenues of $12.8 Million Reported for the Quarter Conference Call Today at 4:30pm Eastern Tim
Read more →VCELVericel Reports Second-Quarter 2016 Financial Results
Total Revenues of $12.8 Million Reported for the Quarter Conference Call Today at 4:30pm Eastern Time CAMBRIDGE, Mass., Aug. 08, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for the treatment of severe dis
Read more →VCELVericel to Host Second-Quarter 2016 Earnings Webcast and Conference Call on August 8, 2016
CAMBRIDGE, Mass., Aug. 01, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced the following webcast and conference call: What: Verice
Read more →VCELVericel to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference
CAMBRIDGE, Mass., July 06, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced that Nick Colangelo, president and CEO, and Gerard Miche
Read more →VCELVericel Corporation 64 Sidney Street Cambridge, MA 02139 T (617) 252-7999 F (617) 252-7550 www.vcel.com Vericel Reports First-Quarter 2016 Financial Results Total Revenues of $14.1 Million Reported for the Quarter Cartic
Exhibit 99.1 Vericel Corporation 64 Sidney Street Cambridge, MA 02139 T (617) 252-7999 F (617) 252-7550 www.vcel.com Vericel Reports First-Quarter 2016 Financial Results Total Revenues of $14.1 Million Reported for the Quarter Carticel and Epicel Revenues Increase 31% ve
Read more →VCELVericel Reports First-Quarter 2016 Financial Results
Total Revenues of $14.1 Million Reported for the Quarter Carticel and Epicel Revenues Increase 31% versus First Quarter 2015 Conference Call Today at 8:00am Eastern Time CAMBRIDGE, Mass., May 10, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer o
Read more →VCELVericel to Host First-Quarter 2016 Earnings Webcast and Conference Call on May 10, 2016
CAMBRIDGE, Mass., April 27, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced the following webcast and conference call: What: Veric
Read more →VCELVericel to Present at 15th Annual Needham Healthcare Conference
CAMBRIDGE, Mass., April 08, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced that Nick Colangelo, president and CEO, will present at
Read more →VCELVericel Corporation 64 Sidney Street Cambridge, MA 02139 T 617 588-5555 F 617 588-5668 www.vcel.com Results from Vericel s Positive Phase 2b ixCELL-DCM Clinical Trial of Ixmyelocel-T Presented Today at ACC and Published
Vericel Corporation 64 Sidney Street Cambridge, MA 02139 T 617 588-5555 F 617 588-5668 www.vcel.com Results from Vericel s Positive Phase 2b ixCELL-DCM Clinical Trial of Ixmyelocel-T Presented Today at ACC and Published in The Lancet Patients Treated with Ixmyelocel-T had a 37
Read more →VCELVericel to Host Review of Positive Phase 2b ixCELL-DCM Trial Results Following American College of Cardiology 65th Annual Scientific Sessions
CAMBRIDGE, Mass., March 29, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, will host a live webcast at 12:00pm ET on Tuesday, April 5, 2016 to rev
Read more →VCELVericel Announces Publication of Clinical Trial Rationale and Study Design for the Phase 2b ixCELL-DCM Trial of Ixmyelocel-T in Patients with Heart Failure Due to Ischemic Dilated Cardiomyopathy
CAMBRIDGE, Mass., March 28, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced the publication of the clinical trial rationale and stu
Read more →VCELVericel Corporation 64 Sidney Street Cambridge, MA 02139 T 617 252-7999 F 617 252-7550 www.vcel.com Vericel Announces Publication of Clinical Trial Rationale and Study Design for the Phase 2b ixCELL-DCM Trial of Ixmyeloc
Vericel Announces Publication of Clinical Trial Rationale and Study Design for the Phase 2b ixCELL-DCM Trial of Ixmyelocel-T in Patients with Heart Failure Due to Ischemic Dilated Cardiomyopathy CAMBRIDGE, Mass., March 28, 2016 (GLOBE NEWSWIRE) Vericel Corporation (NASDAQ: VCEL)
Read more →VCELVericel Reports Fourth-Quarter and Year-End 2015 Financial Results
Total Revenues of $15.4 Million Reported for the Fourth Quarter Conference Call Today at 8:00am Eastern Time CAMBRIDGE, Mass., March 14, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of patient-specific expanded cellular therapies for the treat
Read more →VCELVericel Corporation 64 Sidney Street Cambridge, MA 02139 T (617) 252-7999 F (617) 252-7550 www.vcel.com Vericel Reports Fourth-Quarter and Year-End 2015 Financial Results Total Revenues of $15.4 Million Reported for the
Exhibit 99.1 Vericel Corporation 64 Sidney Street Cambridge, MA 02139 T (617) 252-7999 F (617) 252-7550 www.vcel.com Vericel Reports Fourth-Quarter and Year-End 2015 Financial Results Total Revenues of $15.4 Million Reported for the Fourth Quarter Conference Call Today a
Read more →VCELVericel Announces Positive Top-Line Results From Phase 2b ixCELL-DCM Clinical Trial of Ixmyelocel-T in Patients With Heart Failure Due to Ischemic Dilated Cardiomyopathy
CAMBRIDGE, Mass., March 10, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced top-line results from the company’s Phase 2b ixCELL-DCM
Read more →VCELVericel Corporation 64 Sidney Street Cambridge, MA 02139 T 617 588-5555 F 617 588-5668 www.vcel.com Vericel Announces Positive Top-Line Results from Phase 2b ixCELL-DCM Clinical Trial of Ixmyelocel-T in Patients with Hea
Vericel Announces Positive Top-Line Results from Phase 2b ixCELL-DCM Clinical Trial of Ixmyelocel-T in Patients with Heart Failure Due to Ischemic Dilated Cardiomyopathy Study Meets Primary Endpoint of Reduction in Clinical Cardiac Events CAMBRIDGE, Mass., March 10, 2016 (GLOBE
Read more →VCELVericel Enters Into $10 Million Credit Facility and $5 Million Term Loan Agreement With Silicon Valley Bank
CAMBRIDGE, Mass., March 09, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, announced today that it has entered into a term loan and revolving line
Read more →VCELVericel to Present at 28th Annual ROTH Conference
CAMBRIDGE, Mass., March 08, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced that Nick Colangelo, president and CEO, and Gerard Mich
Read more →VCELVericel Announces FDA Acceptance for Filing of BLA for MACI for the Treatment of Symptomatic Cartilage Defects in the Knee
CAMBRIDGE, Mass., March 07, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced that the U.S. Food and Drug Administration has accepted
Read more →VCELVericel Corporation 64 Sidney Street Cambridge, MA 02139 T 617 252-7999 F 617 252-7550 www.vcel.com Vericel Announces FDA Acceptance for Filing of BLA for MACI for the Treatment of Symptomatic Cartilage Defects in the Kn
Vericel Corporation 64 Sidney Street Cambridge, MA 02139 T 617 252-7999 F 617 252-7550 www.vcel.com Vericel Announces FDA Acceptance for Filing of BLA for MACI for the Treatment of Symptomatic Cartilage Defects in the Knee CAMBRIDGE, Mass., March 7, 2016 (GLOBE NEWSWIRE) Veric
Read more →VCELVericel to Host Fourth-Quarter 2015 Earnings Webcast and Conference Call on March 14, 2016
CAMBRIDGE, Mass., Feb. 26, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced the following webcast and conference call: What: Verice
Read more →VCELVericel to Present at Canaccord Genuity Investor Conference
CAMBRIDGE, Mass., Feb. 24, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced that it will present at the Canaccord Genuity Musculoske
Read more →VCELVericel Announces FDA Approval of Epicel HDE Supplement
CAMBRIDGE, Mass., Feb. 22, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced that the U.S. Food and Drug Administration has approved
Read more →VCELVericel Corporation 64 Sidney Street Cambridge, MA 02139 T 617 252-7999 F 617 252-7550 www.vcel.com Vericel Announces FDA Approval of Epicel HDE Supplement Revised Product Label Includes Indication for Use in Pediatric P
Vericel Announces FDA Approval of Epicel HDE Supplement Revised Product Label Includes Indication for Use in Pediatric Patients and Now Specifies a Probable Benefit of Epicel Mainly Related to Patient Survival CAMBRIDGE, Mass., February 22, 2016 (GLOBE NEWSWIRE) Vericel Corpor
Read more →VCELVericel Corporation 64 Sidney Street Cambridge, MA 02139 T 617 252-7999 F 617 252-7550 www.vcel.com Vericel Submits Biologics License Application to the FDA for MACI for the Treatment of Cartilage Defects in the Knee
Vericel Corporation 64 Sidney Street Cambridge, MA 02139 T 617 252-7999 F 617 252-7550 www.vcel.com Vericel Submits Biologics License Application to the FDA for MACI for the Treatment of Cartilage Defects in the Knee CAMBRIDGE, Mass., Jan. 4, 2016 (GLOBE NEWSWIRE) Vericel Corp
Read more →VCELVericel Submits Biologics License Application to the FDA for MACI for the Treatment of Cartilage Defects in the Knee
CAMBRIDGE, Mass., Jan. 04, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced that it has submitted a Biologics License Application (B
Read more →VCELVericel Submits HDE Supplement to the FDA to Revise the Labeled Indications for Use and Add Pediatric Labeling for Epicel
CAMBRIDGE, Mass., Dec. 8, 2015 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced that it has submitted a Humanitarian Device Exemption (HD
Read more →VCELVericel Corporation 64 Sidney Street Cambridge, MA 02139 T 617 252-7999 F 617 252-7550 www.vcel.com Vericel Submits HDE Supplement to the FDA to Revise the Labeled Indications for Use and Add Pediatric Labeling for Epice
Vericel Submits HDE Supplement to the FDA to Revise the Labeled Indications for Use and Add Pediatric Labeling for Epicel CAMBRIDGE, Mass., December 8, 2015 (GLOBE NEWSWIRE) Vericel Corporation (NASDAQ: VCEL), a leading developer of patient-specific expanded cellular therapies f
Read more →VCELVericel Reports Third-Quarter 2015 Financial Results
Total Revenues of $11.3 Million Reported for the Third Quarter Carticel and Epicel Revenues Increase 19% Compared to Third Quarter of 2014 Conference Call Today at 8:00am Eastern Time CAMBRIDGE, Mass., Nov. 13, 2015 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a lead
Read more →VCELVericel Corporation 64 Sidney Street Cambridge, MA 02139 T (617) 252-7999 F (617) 252-7550 www.vcel.com Vericel Reports Third-Quarter 2015 Financial Results Total Revenues of $11.3 Million Reported for the Third Quarter
Exhibit 99.1 Vericel Corporation 64 Sidney Street Cambridge, MA 02139 T (617) 252-7999 F (617) 252-7550 www.vcel.com Vericel Reports Third-Quarter 2015 Financial Results Total Revenues of $11.3 Million Reported for the Third Quarter Carticel and Epicel Revenues Increase
Read more →VCELVericel to Host Third-Quarter 2015 Earnings Webcast and Conference Call on November 13, 2015
CAMBRIDGE, Mass., Nov. 3, 2015 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced the following webcast and conference call: What: Vericel
Read more →VCELVericel Corporation 64 Sidney Street Cambridge, MA 02139 T 617 252-7999 F 617 252-7550 www.vcel.com Vericel Announces Long-Term Supply Agreement with Matricel for Key Component of
Vericel Announces Long-Term Supply Agreement with Matricel for Key Component of MACI CAMBRIDGE, Mass., October 26, 2015 (GLOBE NEWSWIRE) Vericel Corporation (NASDAQ: VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases a
Read more →VCELVericel Corporation 64 Sidney Street Cambridge, MA 02139 T 617 252-7999 F 617 252-7550 www.vcel.com Vericel Reports Second-Quarter 2015 Financial Results Total Revenues of $13.6 Million Reported for the Second Quarter Ca
Vericel Corporation 64 Sidney Street Cambridge, MA 02139 T 617 252-7999 F 617 252-7550 www.vcel.com Vericel Reports Second-Quarter 2015 Financial Results Total Revenues of $13.6 Million Reported for the Second Quarter Carticel and Epicel Revenues Increase 31% Compared to Seco
Read more →VCELVericel Reports Second-Quarter 2015 Financial Results
Total Revenues of $13.6 Million Reported for the Second Quarter Carticel and Epicel Revenues Increase 31% Compared to Second Quarter 2014 Conference Call Today at 8:00am Eastern Time CAMBRIDGE, Mass., Aug. 12, 2015 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leadi
Read more →VCELVericel to Host Second-Quarter 2015 Earnings Webcast and Conference Call on August 12, 2015
CAMBRIDGE, Mass., July 29, 2015 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced the following webcast and conference call: What: Verice
Read more →VCELVericel Announces Plan to Submit HDE Supplement to the FDA to Revise the Labeled Indications for Use and Add Pediatric Labeling for Epicel
CAMBRIDGE, Mass., July 14, 2015 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced that following discussions with the U.S. Food and Drug A
Read more →VCELVericel Announces Plan to Submit Biologics License Application to FDA by Year-End 2015 for MACI for the Treatment of Cartilage Defects in the Knee
CAMBRIDGE, Mass., June 10, 2015 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced that following discussions with the U.S. Food and Drug A
Read more →VCELVericel Reports First-Quarter 2015 Financial Results
Total Revenues of $10.8 Million Reported for the First Quarter Conference Call Today at 4:30pm Eastern Time CAMBRIDGE, Mass., May 14, 2015 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatmen
Read more →VCELVericel Corporation 64 Sidney Street Cambridge, MA 02139 T 617 252-7999 F 617 252-7550 www.vcel.com Vericel Reports First-Quarter 2015 Financial Results Total Revenues of $10.8 Million Reported for the First Quarter Conf
Vericel Reports First-Quarter 2015 Financial Results Total Revenues of $10.8 Million Reported for the First Quarter Conference Call Today at 4:30pm Eastern Time CAMBRIDGE, Mass., May 14, 2015 (GLOBE NEWSWIRE) Vericel Corporation (NASDAQ: VCEL), a leading developer of patient-s
Read more →VCELVericel to Host First-Quarter 2015 Earnings Webcast and Conference Call on May 14, 2015
CAMBRIDGE, Mass., April 30, 2015 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced the following webcast and conference call: What: Veric
Read more →VCELVericel Reports Three-Year Follow-Up Results From Phase 3 SUMMIT Extension Study of MACI(TM) Implant
CAMBRIDGE, Mass., March 25, 2015 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today reported that positive results from the three-year extension of t
Read more →VCELVericel Reports Fourth-Quarter and Year-End 2014 Financial Results
Total Revenues of $14.7 Million Reported for the Fourth Quarter Conference Call Today at 4:30pm Eastern Time CAMBRIDGE, Mass., March 23, 2015 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of patient-specific expanded cellular therapies for the treat
Read more →VCELVericel Corporation 64 Sidney Street Cambridge, MA 02139 T 617 252-7999 F 617 252-7550 www.vcel.com Vericel Reports Fourth-Quarter and Year-End 2014 Financial Results Total Revenues of $14.7 Million Reported for the Four
Vericel Reports Fourth-Quarter and Year-End 2014 Financial Results Total Revenues of $14.7 Million Reported for the Fourth Quarter Conference Call Today at 4:30pm Eastern Time CAMBRIDGE, Mass., March 23, 2015 (GLOBE NEWSWIRE) Vericel Corporation (NASDAQ: VCEL), a leading devel
Read more →VCELVericel to Present at Canaccord Genuity and ARM Investor Conferences
CAMBRIDGE, Mass., March 18, 2015 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced that it will present at the following investor conferen
Read more →VCELVericel to Host Fourth-Quarter 2014 Earnings Call on March 23, 2015
CAMBRIDGE, Mass., March 12, 2015 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced the following conference call and webcast: What: Veric
Read more →VCELVericel to Present at 27th Annual ROTH Conference
CAMBRIDGE, Mass., March 6, 2015 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced that Nick Colangelo, president and CEO, and Gerard Miche
Read more →VCELVericel Completes Patient Enrollment in Phase 2b ixCELL-DCM Clinical Study of Ixmyelocel-T
CAMBRIDGE, Mass., Jan. 29, 2015 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced the completion of patient enrollment in the company's Ph
Read more →VCELCompany Presentation January 2015 Safe Harbor This presentation contains forward-looking statements, including, without limitation, statements concerning anticipated progress, objectives and expectations regarding profit
Deep experience in restructuring and integrating acquired businesses New Business Focus Restructured Vericel s legacy business in 2013 to focus on orphan disease program Acquired Sanofi s global CTRM business in 2014; revenues of $44 million in 2013 Established Commercial Busines
Read more →VCELVericel Corporation 64 Sidney Street Cambridge, MA 02139 T 617 252-7999 F 617 252-7550 www.vcel.com Vericel Corporation Names Three New Board Members CAMBRIDGE, Mass., JANUARY 7, 2015 (GLOBE NEWSWIRE) Vericel Corporation
Vericel Corporation 64 Sidney Street Cambridge, MA 02139 T 617 252-7999 F 617 252-7550 www.vcel.com Vericel Corporation Names Three New Board Members CAMBRIDGE, Mass., JANUARY 7, 2015 (GLOBE NEWSWIRE) Vericel Corporation (NASDAQ: VCEL), a leading developer of patient-specifi
Read more →VCELVericel Corporation 64 Sidney Street Cambridge, MA 02139 T 617 252-7999 F 617 252-7550 www.vcel.com Aastrom Biosciences Changes Name to Vericel Corporation Headquarters moved to Cambridge, Mass.; New ticker symbol
Aastrom Biosciences Changes Name to Vericel Corporation Headquarters moved to Cambridge, Mass.; New ticker symbol: VCEL CAMBRIDGE, Mass., November 24, 2014 (GLOBE NEWSWIRE) Aastrom Biosciences, Inc. (NASDAQ: ASTM), a leading developer of patient-specific expanded cellular thera
Read more →VCELAastrom Biosciences Reports Third-Quarter 2014 Financial Results Conference Call Today at 8:30 a.m. Eastern Time
Aastrom Biosciences Reports Third-Quarter 2014 Financial Results Conference Call Today at 8:30 a.m. Eastern Time ANN ARBOR, Mich., November 13, 2014 (GLOBE NEWSWIRE) Aastrom Biosciences, Inc. (Nasdaq: ASTM), a leading developer of patient-specific expanded cellular therapies fo
Read more →VCELAastrom Biosciences Announces Plans to Change Name to Vericel Corporation and Move Headquarters to Cambridge, Massachusetts
Aastrom Biosciences Announces Plans to Change Name to Vericel Corporation and Move Headquarters to Cambridge, Massachusetts ANN ARBOR, Mich., October 9, 2014 (GLOBE NEWSWIRE) Aastrom Biosciences, Inc. (Nasdaq: ASTM), a leading developer of patient-specific expanded cellular ther
Read more →VCELAastrom Biosciences Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares
Aastrom Biosciences Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares ANN ARBOR, Mich., September 17, 2014 (GLOBE NEWSWIRE) Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of patient-specific
Read more →VCELAastrom Biosciences Announces Pricing of Public Offering of Common Stock
Aastrom Biosciences Announces Pricing of Public Offering of Common Stock ANN ARBOR, Mich., September 11, 2014 (GLOBE NEWSWIRE) Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and
Read more →VCELAastrom Biosciences Reports Second Quarter 2014 Financial Results U.S. Commercial Business Generates Positive Contribution Conference Call Today at 8:30 a.m. Eastern Time
Aastrom Biosciences Reports Second Quarter 2014 Financial Results U.S. Commercial Business Generates Positive Contribution Conference Call Today at 8:30 a.m. Eastern Time ANN ARBOR, Mich., August 14, 2014 (GLOBE NEWSWIRE) Aastrom Biosciences, Inc. (Nasdaq: ASTM), a leading dev
Read more →VCELAastrom Biosciences Domino s Farms, Lobby K 24 Frank Lloyd Wright Drive Ann Arbor, MI 48105 T 734 418 4400 F 734 665 0485 www.aastrom.com For Immediate Release Aastrom Announces Strategic Plan for Recently Acquired Cell
Aastrom Biosciences Domino s Farms, Lobby K 24 Frank Lloyd Wright Drive Ann Arbor, MI 48105 T 734 418 4400 F 734 665 0485 www.aastrom.com Aastrom Announces Strategic Plan for Recently Acquired Cell Therapy and Regenerative Medicine Business Manufacturing of MACI in Denmark to
Read more →VCELAastrom Biosciences Domino s Farms, Lobby K 24 Frank Lloyd Wright Drive Ann Arbor, MI 48105 T 734 418 4400 F 734 665 0485 www.aastrom.com Aastrom Announces Appointment of Gerard Michel as Chief Financial Officer and Vice
Aastrom Announces Appointment of Gerard Michel as Chief Financial Officer and Vice President, Corporate Development Accomplished industry veteran brings extensive history of successful corporate development, fundraising and capital management to Aastrom ANN ARBOR, Mich., June 4
Read more →VCELAastrom Biosciences Domino s Farms, Lobby K 24 Frank Lloyd Wright Drive Ann Arbor, MI 48105 T 734 418 4400 F 734 665 0485 www.aastrom.com For Immediate Release Aastrom Completes Acquisition of Sanofi s Cell Therapy and R
Aastrom Completes Acquisition of Sanofi s Cell Therapy and Regenerative Medicine Business ANN ARBOR, Mich., June 2, 2014 (GLOBE NEWSWIRE) Aastrom Biosciences, Inc. (Nasdaq: ASTM), the leading developer of patient-specific expanded cellular therapies for the treatment of severe d
Read more →VCELAastrom Biosciences Domino s Farms, Lobby K 24 Frank Lloyd Wright Drive Ann Arbor, MI 48105 T 734 418-4400 F 734 665-0485 www.aastrom.com Aastrom Announces Definitive Agreement to Acquire Sanofi s Cell Therapy and Regene
Aastrom Biosciences Domino s Farms, Lobby K 24 Frank Lloyd Wright Drive Ann Arbor, MI 48105 T 734 418-4400 F 734 665-0485 www.aastrom.com Aastrom Announces Definitive Agreement to Acquire Sanofi s Cell Therapy and Regenerative Medicine Business Acquisition of landmark autolog
Read more →VCELAastrom Announces Appointments of Dr. Ross Tubo as Chief Scientific Officer and Dr. David Recker as Chief Medical Officer Globally recognized industry veterans bring extensive R&D and product development experience in re
Aastrom Announces Appointments of Dr. Ross Tubo as Chief Scientific Officer and Dr. David Recker as Chief Medical Officer Globally recognized industry veterans bring extensive R&D and product development experience in regenerative medicine and multiple therapeutic areas ANN ARB
Read more →VCELAastrom Biosciences Enters into $15 Million Equity Commitment with Lincoln Park Capital
Aastrom Biosciences Enters into $15 Million Equity Commitment with Lincoln Park Capital ANN ARBOR, Mich., January 27, 2014 (GLOBE NEWSWIRE) Aastrom Biosciences, Inc. (Nasdaq: ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of
Read more →VCELAastrom Biosciences Reports Third-Quarter and Nine-Month 2013 Financial Results Conference Call
Aastrom Biosciences Reports Third-Quarter and Nine-Month 2013 Financial Results Conference Call November 12, 2013 at 4:30 PM Eastern Time ANN ARBOR, Mich., November 12, 2013 (GLOBE NEWSWIRE) Aastrom Biosciences, Inc. (Nasdaq: ASTM), the leading developer of patient-specific, ex
Read more →VCELAastrom Biosciences Announces One-for-Twenty Reverse Stock Split
Aastrom Biosciences Announces One-for-Twenty Reverse Stock Split ANN ARBOR, Mich., October 10, 2013 - Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe chronic cardiovascular diseases,
Read more →VCELAastrom Biosciences, Inc. Announces Pricing of Public Offering of Common Stock and Warrants
Aastrom Biosciences, Inc. Announces Pricing of Public Offering of Common Stock and Warrants ANN ARBOR, Michigan, August 13, 2013 Aastrom Biosciences, Inc. (Nasdaq: ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chr
Read more →VCELAastrom Biosciences Announces Amendment of Series B Preferred Stock Certificate of Designations, Preferences and Rights Amendment Increases Shareholders Equity by $37.7 Million
Aastrom Biosciences Announces Amendment of Series B Preferred Stock Certificate of Designations, Preferences and Rights Amendment Increases Shareholders Equity by $37.7 Million ANN ARBOR, Mich., August 12, 2013 (GLOBE NEWSWIRE) Aastrom Biosciences, Inc. (Nasdaq: ASTM), the lead
Read more →VCELAastrom Biosciences Reports Second-Quarter and First-Half 2013 Financial Results Conference Call
Aastrom Biosciences Reports Second-Quarter and First-Half 2013 Financial Results Conference Call August 15, 2013 at 4:30 PM Eastern Time ANN ARBOR, Mich., August 7, 2013 (GLOBE NEWSWIRE) Aastrom Biosciences, Inc. (Nasdaq: ASTM), the leading developer of patient-specific, expand
Read more →VCELAastrom Biosciences Reports First Quarter 2013 Financial Results Conference call today at 4:30 PM Eastern time
Aastrom Biosciences Reports First Quarter 2013 Financial Results Conference call today at 4:30 PM Eastern time ANN ARBOR, Mich., May 8, 2013 (GLOBE NEWSWIRE) Aastrom Biosciences, Inc. (Nasdaq: ASTM), the leading developer of patient-specific expanded multicellular therapies for
Read more →VCELAastrom Biosciences The Future of Cell Therapy April 2013 Safe Harbor This presentation contains forward-looking statements, including, without limitation, statements concerning product-development objectives, clinical t
Catheter (CATHETER-DCM Study) Patient Population: Ischemic vs. non-ischemic DCM IMPACT-DCM (n=39) CATHETER-DCM (n=21) Delivery Intramyocardial delivery to the myocardium via thoracotomy Endocardial injections delivered via NOGASTAR endomyocardial catheter Ixmyelocel-T Control Ixm
Read more →VCELAastrom Biosciences Domino s Farms, Lobby K 24 Frank Lloyd Wright Drive Ann Arbor, MI 48105 T 734 418-4400 F 734 665-0485 www.aastrom.com For Immediate Release Aastrom Biosciences Announces Strategic Change in Research a
Aastrom Biosciences Announces Strategic Change in Research and Development Programs to Focus on Dilated Cardiomyopathy and Other Rare Disease Indications Focus shifted to Phase 2b ixCELL-DCM clinical study and the development of ixmyelocel-T for dilated cardiomyopathy, an orph
Read more →VCELAastrom Biosciences Domino s Farms, Lobby K 24 Frank Lloyd Wright Drive Ann Arbor, MI 48105 T 734 418-4400 F 734 665-0485 www.aastrom.com For Immediate Release Aastrom Board of Directors Names Dominick C. Colangelo Presi
Aastrom Board of Directors Names Dominick C. Colangelo President and Chief Executive Officer ANN ARBOR, Mich., [March 6, 2013] Aastrom Biosciences, Inc. (Nasdaq: ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chro
Read more →VCELAastrom Biosciences Domino s Farms, Lobby K 24 Frank Lloyd Wright Drive Ann Arbor, MI 48105 T 734 418-4400 F 734 665-0485 www.aastrom.com Draft For Review Aastrom Board of Directors Names Dan Orlando Interim CEO ANN ARBO
Aastrom Biosciences Domino s Farms, Lobby K 24 Frank Lloyd Wright Drive Ann Arbor, MI 48105 T 734 418-4400 F 734 665-0485 www.aastrom.com Aastrom Board of Directors Names Dan Orlando Interim CEO ANN ARBOR, Mich., [Dec. 12, 2012] Aastrom Biosciences, Inc. (Nas
Read more →Competitive Position
How VCEL ranks across every disease it competes inCompetitive Position is a premium feature
See how VCEL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial